Experts & Associates

The Mirrors of Medicine PinPoint cases are reviewed and validated by multidisciplinary expert panels. Selection of experts is based on two principal criteria: extensive scientific output and considerable clinical experience within the subject disease area. In addition, a reasonable geographic spread is sought.

Preparation of cases is done together with experts and their dedicated team members (associates).

Verane Achard

Verane Achard

Geneva University Hospitals, Radiation Oncology

Geneva, Switzerland

Disease area: Prostate cancer

Biography:
Vérane Achard is a specialist in Radiation Oncology at the University Hospitals of Geneva, Switzerland. After obtaining her master’s degree in Engineering at the INP-Phelma in Grenoble, France, she finished her PhD in Physics for Life Sciences at the French Alternative Energies and Atomic Energy Commission (CEA) in 2009. She completed residencies at the departments of Radiation Oncology of the Grenoble Alpes University Hospital in France, and the University Hospitals of Geneva in Switzerland, before obtaining her MD in Radiation Oncology in 2019. The fields of interest of Dr. Achard include high-precision radiotherapy techniques (SBRT, IGRT, VMAT) and genitourinary cancer treatment, specifically treatment of oligometastatic prostate cancer. Dr. Achard received the Scientific Association of Swiss Radiation Oncology (SASRO) 2019 best academic presentation award and young researcher grant. She has (co-)authored 10 peer-reviewed publications.

See COI

Laurence Albiges

Laurence Albiges

Gustave Roussy Institute, Medical Oncology

Villejuif, France

Disease area: Renal Cell Carcinoma

Biography:
Laurence Albiges is the Head of the Genitourinary Unit at Gustave Roussy Institute, Villejuif, France. She joined the Genitourinary group at Gustave Roussy in 2011 after completing her training as Medical Oncologist in Paris, France. Her main field of interest across genitourinary tumours is new targets in renal cell carcinoma and non-clear cell renal carcinoma. She was a visiting scientist at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute in Boston, MA, USA from 2013 to 2015, where she worked on Papillary RCC and the Biobank of the International Metastatic RCC Database Consortium (IMDC). Since 2015, she is in charge of the Genitourinary Tumor Board at the Gustave Roussy Institute and member of the GETUG board. She is an ESMO faculty and ASCO member and was awarded several ASCO Merit Awards for her work. Since 2016, she joined the Renal Cell Carcinoma Guidelines panel of EAU.

See COI

Antonio Alcaraz

Antonio Alcaraz

University of Barcelona, Urology

Barcelona, Spain

Disease area: Prostate cancer

Biography:
Antonio Alcaraz is Professor of Surgery at the University of Barcelona, Spain. He received his medical degree in 1983, and his PhD in 1987, both from the University of Barcelona. After a 5 year residency in urology at the University Hospital Clinic in Barcelona, he became a member of the Spanish Board of Urology in 1988. He completed a research fellowship at the Mayo Clinic in Rochester, USA between 1993 and 1994. Professor Alcaraz was Head of the Transplant and Oncology Unit of the Department of Urology at Fundacio Puigvert between 2002 and 2005. Since February 2005, he has been Chair of the Department of Urology at the University Hospital Clinic of Barcelona, and was Chair of the Transplant Section (2004-2008) and then Secretary General of the Spanish Association of Urology (2008-2012). Professor Alcaraz’s research interests include major uro-oncological, laparoscopic and transplant surgery, being pioneer in single port surgery and transvaginal nephrectomy. Most of his translational research has been done on cancer genetics. He has authored more than 225 international and Spanish publications. He has been a member of the board of the European School of Urology, and member of the Scientific Committee of the European Association of Urology (2010-2016).

See COI

Carolina Alves Costa-Silva (Associate)

Carolina Alves Costa-Silva (Associate)

Gustave Roussy Institute, Medical Oncology

Villejuif, France

Disease area: Renal Cell Carcinoma

Biography:
Carolina Alves obtained her medical degree from the Federal University of Bahia in Salvador, Brazil, in 2012. After her graduation, she obtained a position in the internal medicine residency program at Hospital das Clínicas and subsequently in the oncology fellowship program at Instituto do Câncer do Estado de São Paulo, both part of of the Academic Health Center of the University of São Paulo in São Paulo, Brazil. After her fellowship, she joined a multidisciplinary cancer team as a clinical oncologist at Núcleo de Oncologia da Bahia, a partner center of Oncoclínicas Brazil. In November 2018, she had the pleasure of starting the DUERTECC program at the Gustave Roussy Institute in Villejuif, France, with the project “Metabolic impact of Cabozantib treatment in patients with metastatic renal cell carcinoma”, under the supervision of Dr Laurence Albiges. Following her research work, she received the grant from A.R.Tu.R. (Association pour la Recherche sur les Tumeurs du Rein) and she started working as a research fellow at laboratory U1015, under the supervision of Pr Laurence Zitvogel and Dr Lisa Derosa. Their work aims to improve knowledge and understanding of the functional relevance of the gut microbiome in kidney cancer.

See COI

Tom Arends (Associate)

Tom Arends (Associate)

Antoni van Leeuwenhoek Ziekenhuis Amsterdam, Urology

Amsterdam, Netherlands

Disease area: Renal Cell Carcinoma

Biography:
Tom Arends obtained his medical degree in 2012 from the Radboud University Medical Centre in Nijmegen, The Netherlands. After his graduation, he started as a PhD candidate at the Urology Department. He defended his thesis on bladder cancer in June 2016 and simultaneously started as a urology resident. He won several scientific prizes with his thesis. In 2017, he received the “Residents’ Best Scientific Paper Award” for a publication in European Urology. At the end of 2020, he will finish his urology residency and start as urologist in Amersfoort, The Netherlands.

See COI

Amit Bahl

Amit Bahl

Bristol Haematology & Oncology Centre, Clinical Oncology

Bristol, United Kingdom

Disease area: Prostate cancer,Renal Cell Carcinoma

Biography:
Amit Bahl is Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol and Clinical Director of Spire Specialist Care Centre with a special interest in breast and urological cancers. He is the research lead for Uro-oncology at Bristol Cancer Institute, and led and developed the prostate brachytherapy service in Bristol. He has been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country. He has more than 100 peer reviewed publications. Dr Bahl trained in Clinical Oncology, achieving Fellowship of the Royal College of Radiologists, and has been elected as a fellow of the Royal College of Physicians. Currently, he is a member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer, and chairs the penile cancer subgroup. He is also an Executive Committee member of the British Uro-oncology group. In 2012, Dr Bahl was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London, and he is Visiting Professor to two international centres and at University of West of England.

See COI

Aristotelis Bamias

Aristotelis Bamias

University of Athens, Medical Oncology

Athens, Greece

Disease area: Bladder cancer,Renal Cell Carcinoma

Biography:
Aristotelis Bamias, MD, PhD, is Professor at the Medical School, University of Athens, in Greece. He studied Μedicine in the Medical School of the University of Athens and trained in Ιnternal Μedicine and Μedical Οncology in the UK where he served as Lecturer in Medical Oncology at the University of London. He is affiliated with the Department of Clinical Therapeutics of the University of Athens at the Alexandra Hospital in Athens, where he is in charge of the laboratory of the Oncology Unit. He is a founding member and Chair of the Hellenic Genito-Urinary Cancer Group (HGUCG). He is a member of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Professor Bamias has been a member of the European Society of Medical Oncology (ESMO) Faculty for Genitourinary Cancer since 2012 and he is currently chairing this group. He is a member of the ESMO Educational Committee and a member of the Scientific Committee of the ESMO 2016-2019 Congresses. His main research focus in oncology is urogenital and gynaecological tumours and he has been invited speaker in many international Congresses on subjects related to these malignancies. A member of several international advisory boards and steering committees of international trials, he has published more than 240 original papers and reviews in peer-reviewed journals with more than 8000 citations by other authors and a current h-index of 44.

See COI

Nicolò Matteo Luca Battisti

Nicolò Matteo Luca Battisti

The Royal Marsden NHS Foundation Trust, Medical Oncology

London, United Kingdom

Disease area: Breast cancer

Biography:
Dr Nicolò Matteo Luca Battisti is a senior clinical research fellow in medical oncology at the Breast Unit of The Royal Marsden NHS Foundation Trust, London, UK. He gained his medical degree at the University of Milan, Italy in 2009 and he completed his specialist training at the University of Milan and National Cancer Institute of Milan, Italy in 2015. He spent the last year of his specialist training working on several research projects at the Senior Adult Oncology Program of the Moffitt Cancer Center of Tampa, Florida, USA under the supervision of Dr Martine Extermann. Dr Battisti joined the Breast Unit of The Royal Marsden NHS Foundation Trust in 2016 and he currently works there under the supervision of Dr Alistair Ring and Prof Stephen Johnston. In September 2019 he started a research degree (MD[Res]) at the Institute of Cancer Research of London, UK focusing on different aspects of the care of common malignancies in older adults. Dr Battisti’s main clinical and research interests are breast oncology and geriatric oncology. He authored several book chapters and publications in the fields of geriatric and breast oncology. He is chair of the Young Interest Group of the International Society of Geriatric Oncology (SIOG) and co-chair of the European Cancer Organisation (ECCO) Inequality Focused Topic Network.

See COI

Anders Bjartell

Anders Bjartell

Lund University, Urology

Lund, Sweden

Disease area: Prostate cancer

Biography:
Anders Bjartell MD, PhD FEBU graduated from Lund University Medical School, Sweden, in 1986. He was a research fellow at the National Institutes of Health in Bethesda, Maryland, USA, from 1988 to 1989, and received his PhD in Medical Cell Research from Lund University in 1990. After training at the University Hospital in Malmö, he became Specialist in Urology in 1998, and received his Fellows of the European Board of Urology (FEBU) diploma in 1999. He was appointed Associate Professor at Lund University in 1995. Professor Bjartell was a Clinical Investigator at the Department of Urology, Memorial Sloan Kettering Cancer Center in New York, USA, from 2005 to 2007, Associate Editor for European Urology from 2005 to 2012, and he is past-president and board member of the European Association of Urology (EAU) Section of Urological Research (ESUR) and board member of EAU Guidelines Office. Professor Bjartell was appointed Chairman of the EAU Research Foundation in 2017 and since 2016 he is Board member of the EAU Guidelines Office. In 2006, Professor Bjartell became full Professor in Clinical Urology, and Senior Consultant at Skåne University Hospital in Malmö. In 2012, he was appointed Assistant Dean at the Medical Faculty, Lund University. Professor Bjartell is also a national principal investigator for several trials of new drugs in castration resistant prostate cancer and Head of the clinical trial unit at the Urology Department at Skåne University Hospital. He leads a research group in translational prostate cancer research with long term experience in prostate cancer biomarkers. His research also encompasses clinical projects on robotic surgery, imaging, and drug development. He has participated in several EU-sponsored prostate cancer projects, and he has published more than 258 peer reviewed original articles.

See COI

Alberto Bossi

Alberto Bossi

Gustave Roussy Institute, Radiation Oncology

Villejuif, France

Disease area: Prostate cancer

Biography:
Dr Alberto Bossi is currently Head of the Urology and Prostate Brachytherapy Unit at the Gustave Roussy Cancer Institute in Villejuif, France. His professional career started in Italy where he was born: he graduated in Medicine and Surgery in 1988 and specialized in Radiotherapy and Diagnostic Radiology in 1992 at the University of Pavia. After a Clinical Fellowship at the Dept of Radiation Oncology at the Academic Medical Centre in Amsterdam he worked in Como and Milan. In 2001 he was appointed Adjunct Clinical Head at the Department of Radiation Oncology of the University Hospital in Leuven, Belgium where he worked till 2006 before moving to IGR. Dr Bossi is member of several scientific societies, including ESTRO, ASTRO, EAU. He has served as Coordinator of the Genito-Urinary Working Group of the EORTC in 2006. He is the Course Director of the Multidisciplinary ESTRO-EAU-ESMO Teaching Course on Prostate Cancer and teacher at both the ESO (European School of Oncology) and EAU (European Association of Urology) Prostate Courses. He is PI and co-PI (Principal Investigator) of two major European Phase III trials on Prostate Cancer and has published over 40 papers in peer-reviewed journals. Dr Bossi is reviewer for several journals including the IJROBP, European Urology, Radiotherapy and Oncology, Annals of Oncology.

See COI

Sergio Bracarda

Sergio Bracarda

Azienda Ospedaliera S. Maria, Medical Oncology

Terni, Italy

Disease area: Bladder cancer,Renal Cell Carcinoma

Biography:
Sergio Bracarda, MD is currently the Director of the Division of Medical Oncology, Department of Oncology, Azienda Ospedaliera S. Maria, Terni, Italy. Dr Bracarda graduated from the School of Medicine, University of Perugia in 1986, specialised in Medical Oncology at the Sacred Heart Catholic University of Rome, Italy, and in Urology at the University of Perugia, where he later became a Resident in the Department of Medical Oncology. Prior to taking up his current position, Dr Bracarda was first Junior, then Senior Registrar/Consultant Oncologist, in the Department of Urology, University of Perugia, then Senior Oncologist and Section Chief of Oncology-Urology in the Medical Oncology Division, Policlinico Hospital, Perugia and Director of the Medical Oncology Unit, Department of Oncology and Prostate Unit in Arezzo, Italy. His current research interests are genitourinary oncology, and particularly prostate cancer, renal cell carcinoma and urothelial cancer, central nervous system and gastrointestinal tumours, treatment approaches that combine biological agents with traditional drugs and schedule optimization. Dr Bracarda has published 151 articles in peer-reviewed journals, more than 700 abstracts, and a number of text book chapters. He was Board Member (Councillor) of the Italian Association of Medical Oncology (AIOM) and is Board Member of the Italian Society for Urology-Oncology (SIUrO). Moreover, he is a Reviewer for several Oncological and Urological journals. Dr Bracarda’s society memberships include the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), the European Association of Urology (EAU), the Italian Society of Medical Oncology (AIOM), the Italian Society of Urology (SIU) and the Italian Society for Urology-Oncology (SIUrO).

See COI

Etienne Brain

Etienne Brain

Institut Curie, Medical Oncology

Paris & Saint-Cloud, France

Disease area: Breast cancer

Biography:
Etienne Brain has been working since 1998 as a medical oncologist at Institut Curie, Paris and Saint-Cloud, France. He obtained his MD in Medical Oncology from Paris-Descartes University in 1995, as well as a PhD in Pharmacology (2005) after initiating (pre)clinical works on alkylation at the Dana Farber Cancer Institute and Boston University, Boston, USA (1995-1996). He received a diploma to supervise research from Saint-Quentin University, Versailles, France (2010) and in Management and Health Economics from Bocconi University, Milan, Italy (2014-2015). Etienne Brain is strongly involved both in breast cancer research and management of older cancer patients, as best epitomized by the large phase III program ASTER 70s (Adjuvant Systemic Treatment for ER+ HER2- breast carcinoma in women over 70 according to genomic grade). As an active member in the Unicancer organization, he is the current chair of the EORTC Breast Cancer Group. He is a board member of the Breast International Group (BIG) and the European Breast Cancer Conference (EBCC). He is also a member of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) steering committee. He is former president of SIOG (International Society of Geriatric Oncology). Since 2014, he is the co-organizer of the SIOG International Course in Geriatric Oncology with the Catholic University of the Sacred Heart in Treviso, Italy. He is (co)author of several publications in peer reviewed journals, including the JAMA, Lancet Oncology, Annals of Oncology and Journal of Clinical Oncology. He is a member of the Editorial Boards of the Breast and the Journal of Geriatric Oncology. He is an active member of ESMO and ASCO.

See COI

User avatar

Douglas Brand (Associate)

Royal Marsden NHS Foundation Trust, Clinical Oncology

London, United Kingdom

Disease area: Prostate cancer

Biography:
To be added

Dejan Bratus

Dejan Bratus

University Medical Centre Maribor, Urology

Maribor, Slovenia

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr. Bratuš was born on February 8th 1964 in Maribor, Slovenia. After finishing grade school, he continued studying on Prva Gimnazija high school in Maribor, of which he finished three years. He attended his senior high school year on Pearl River High School in Pearl River, New York, USA, where he graduated in 1982. After that he began with the study of medicine on Medical Faculty of University in Ljubljana and successfully finished it in 1991. First he completed one year of internship in General Hospital Maribor, where he also stayed to specialize in urology. He finished his training in 1997 and became an urologist. He is currently a head of the Department of Urology at the University medical center Maribor. He has attended the postgraduate study of urology on Medical Faculty of University in Zagreb, Croatia, where he successfully completed it and became a bachelor of science in 2005. He is currently preparing his PhD thesis at the Medical Faculty of University in Maribor. He is a member and current president of Slovenian Urological Association and he is also a member of European Association of Urology (EAU) and European Society for Sexual Medicine (ESSM). he has also founded a Slovenian affiliation to ESSM, Society for Sexual Medicine of Slovenia (SSMS), of which he is also currently the president. Above that he is at the moment the national coordinator of urological specialization at Medical chamber of Slovenia.

See COI

Alberto Briganti

Alberto Briganti

Vita-Salute University San Raffaele, Urology

Milan, Italy

Disease area: Prostate cancer

Biography:
Dr Briganti works as Urologist at Vita-Salute University, San Raffaele Hospital, Milan, Italy. He is a member of several national and international associations as well as being a member of the European Urology Editorial Board at Large. He is a fellow of the European Board of Urology and is also a reviewer of the main urological journals. He is author and co-author of more than 150 papers published in peer reviewed, indexed Journals. His main clinical interests are urological oncology, including development and validation of several prognostic staging tools, and sexual medicine, including erectile dysfunction and male sexual health. He has contributed to the development of several multi-institutional data-bases for prostate cancer staging and outcomes which have been used for improving currently available prediction models.

See COI

Laurence Buisseret (Associate)

Laurence Buisseret (Associate)

Jules Bordet Institute, Medical Oncology

Brussels, Belgium

Disease area: Breast cancer

Biography:
Laurence Buisseret, MD, PhD, is a medical oncologist at the Institut Jules Bordet, Brussels, Belgium. She earned a medical degree from the Université Libre de Bruxelles (ULB) in 2007 and then trained in medical oncology with a focus on breast cancer at the Institut Jules Bordet. From 2014 to 2016, she worked as a research fellow at the Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Canada, in a laboratory specialized in the design of targeted therapies using immune strategies in preclinical models and translational research in immuno-oncology. After obtaining her PhD degree in 2017, she started working in the Medical Oncology Clinic and in the Breast Cancer Translational Research Laboratory (BCTL) at the Institut Jules Bordet. Her clinical and laboratory research focuses on cancer immunotherapy and she is involved in the development of therapeutic strategies to strengthen anti-tumor immunity in breast cancer.

See COI

Fatima Cardoso

Fatima Cardoso

Champalimaud Clinical Centre, Medical Oncology & Internal Medicine

Lisbon, Portugal

Disease area: Breast cancer

Biography:
Dr Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Center (CCC) in Lisbon, Portugal. She is board certified in medical oncology and internal medicine. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI). She returned to Portugal in October 2010 to create the Breast Unit of the CCC, leading it to become the first certified breast unit in Portugal. Her research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in many phase I-IV breast cancer clinical trials. Dr Cardoso is active in numerous professional organizations such as ESO, ESMO, EORTC, ASCO, and AACR, where she serves on several committees. Dr Cardoso founded, and is chair of, the Advanced Breast Cancer (ABC) Global Alliance and of the ABC International Consensus Guidelines Conference. She is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology, the European Cancer Organization, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the "Fonds Jean-Claude Heuson", the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union. She was awarded the prestigious Order of Santiago da Espada for Scientific Merit, from the President of Portugal, on June 10th, 2015. She also received the Flims Alumni Club (FAC) Lifetime Achievement Award 2011; the Prix Nice - St Paul 2017, for the work developed for Advanced Breast Cancer Patients; the Reach to Recovery International Health Professional Award 2019, for exceptional contributions by a health professional in the field of breast cancer support; and the ABC Award 2019, in recognition of her foresight in understanding the importance of advanced breast cancer and for launching a Global Alliance against it. Dr Cardoso has authored about 300 publications and has presented her work nationally and internationally.

See COI

Amar Challapalli

Amar Challapalli

Bristol Haematology & Oncology Centre, Clinical Oncology

Bristol, United Kingdom

Disease area: Prostate cancer,Bladder cancer,Renal Cell Carcinoma

Biography:
Dr. Amarnath Challapalli is a Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol UK, specialising in the management of urological cancers and non-melanomatous skin cancer with radiotherapy, chemotherapy and immunotherapy. He is the chair of the clinical governance committee and a member of the Medicines advisory group (MAG). He is a faculty member on courses in the Royal College of Radiologists. Dr. Challapalli undertook his medical and postgraduate training in clinical oncology in India and in the UK, achieving Fellowship of the Royal College of Radiologists. He subsequently completed a PhD at Imperial College, London in January 2014. His research focused on the translation of novel PET tracers looking at cell proliferation, apoptosis and choline metabolism into clinical studies to look at early response assessment to treatment. His work has been published in peer-reviewed journals and presented at national and international meetings. Dr. Challapalli is actively involved in research into urological and non-melanoma skin cancers, participates in clinical trials locally and nationally and regularly publishes articles in these research areas.

See COI

Ananya Choudhury

Ananya Choudhury

Christie NHS Foundation Trust, Clinical Oncology

Manchester, United Kingdom

Disease area: Bladder cancer

Biography:
Dr Choudhury is a Reader and Honorary Consultant Clinical Oncologist. She joined The Christie in 2008 specialising in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. She is clinical lead for advanced radiotherapy including the MRLinac project and is co-Group Leader of The Translational Radiobiology Group within the Institute of Cancer Sciences. Dr Choudhury currently undertakes research which aims to optimise and personalise radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimising side effects and predictive biomarkers to determine which patients benefit from different treatments. Dr Choudhury graduated from Trinity College, Cambridge, but undertook her Clinical Oncology training at the Yorkshire Deanery from 2000-2008. Between 2005 and 2007, she was a Cancer Research UK Clinical Training Research Fellow and she undertook her PhD at the University of Leeds and Princess Margaret Hospital in Toronto, Canada. For her PhD she studied the molecular epidemiology of DNA double strand break repair in bladder cancer and the use of imatinib (a tyrosine kinase inhibitor) for enhanced chemosensitivity and radiosensitivity. She has a lead role in education and training for specialist registrars and clinical fellows. Dr Choudhury is a member of a member of work stream 2 of the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad) and of the NCRI Bladder Clinical Studies Group. She has also been a member of the NICE bladder cancer guideline development group. Dr Choudhury is the Senior Editor for Genito-urinary cancers for the International Journal of Radiation Oncology • Biology • Physics (The Red Journal).

See COI

Milena Cojić

Milena Cojić

Primary Health Care Center, University of Montenegro, Family Medicine

Podgorica, Montenegro

Disease area: COVID-19

Biography:
Dr. Milena Cojić is a Teaching Associate at the Faculty of Medicine, University of Montenegro, in Family Medicine and General Medicine. She obtained the MD at the School of Medicine of the University of Belgrade, Serbia, in 2009. Formerly she covered the role of teaching assistant at the Faculty of Medicine of the University of Montenegro in Family medicine (2015-2017). Since 2017 Dr. Cojić is a Board certified specialist in Family Medicine (School of Medicine, University of Montenegro, Montenegro) and received in 2020 the Doctor’s degree at the School of Medicine of the University of Nis, Serbia. Dr. Cojić is actively involved in diverse projects, holding the role of Vice-President of the Association of General / Family doctors of Montenegro and contributing as National Representative of Montenegro in EURACT and EPCCS. She is an active member of Working Groups for the development of national guidelines both on uncomplicated urinary tract infections and on acute respiratory tract infections (2019) and collaborated to the national project “Salt survey consumption in Montenegro” (2017, WHO and Ministry of Health of Montenegro and Primary Health Care Center, Podgorica).

See COI

Eva Compérat

Eva Compérat

Hôpital TNN, UPMC Paris VI, Pathology

Paris, France

Disease area: Bladder cancer

Biography:
Professor Eva Compérat is the head of the Pathology Department in Tenon Hospital, Sorbonne University in Paris. She is member of the French Cancer Committee for Bladder Cancer, and also member of the EAU guidelines in the NMIBC (non-muscle invasive) and MIBC (muscle invasive) committee as well as in the Penile carcinoma guidelines group. She is interested in clinical, but also basic research in the field of uropathology, in which she is specialized. She obtained her MD in Vienna, her PhD in Paris, and the right to lead research groupsC. She studied the molecular and morphologic events in the urothelial carcinogenesis, and is linked to the research group (GRC 5) of Pr Cussenot, Sorbonne University. She has also participated to some substantial works regarding prostate and kidney cancer. Professor Compérat’s primary clinical interest is uropathology, she is known in Europe for her diagnostic skills and receives more than 200 consulting cases from all over the world per year. She has published several book chapters and is one of the co-authors of the WHO 2016 Classification of Tumours of the Urinary System and Male Genital Organs (responsible of 3 chapters, co-author in 4 others). She has authored more than 300 papers and is present in many national and international conferences. Professor Compérat also gives many courses in France and abroad and is involved in many international collaborations as well in Europe, but also with the North American continent.

See COI

Evandro De Azambuja

Evandro De Azambuja

Jules Bordet Institute, Medical Oncology

Brussels, Belgium

Disease area: Breast cancer

Biography:
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium. Dr de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B.) in December 2015. His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer (some of them practice changing in breast cancer) such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Alexandra (adjuvant atezolizumab in triple negative breast cancer) and – in the neoadjuvant setting – the LORELEI trial which tested the efficacy of PI3K inhibition in combination with endocrine therapy. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past chair of the survivorship of the Belgian Society of Medical Oncology (BSMO). Dr. de Azambuja was a member of the ESMO Executive Board (2018), and currently is an ESMO Council Member (2019) and the chair of the ESMO Fellowship Committee (mandate started in January 2018). He was a member of the ESMO Young Oncologists Committee (YOC) and the ESMO Press & Media Affairs Committee. He is also a faculty member of the ESMO Leaders’ Generation Program launched in 2016-2017 and Co-chair of this Programme since 2018. He was appointed as a Breast Faculty Member of ESMO in 2017 and was a board member of the BSMO 2015-2019. He was appointed as the chair of the ESMO Leaders Generation Programme Task Force in January 2019. Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the BSMO. He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspective. He has (co)-authored about 200 peer-reviewed articles and 15 book chapters. He has been a member of Education and Scientific Committees of the ESMO, ESMO breast, EBCC and ECCO meetings.

See COI

Alexandre de la Taille

Alexandre de la Taille

CHU Henri Mondor, Assistance Publique des Hopitaux de Paris, Urology

Créteil, France

Disease area: Prostate cancer

Biography:
Professor Alexandre de la Taille is head of Urology Department in CHU Mondor Assistance Publique des Hopitaux de Paris in France and also head of the Inserm U955Eq07 research team on translational research in uro-oncology. He has been involved in uro-oncology for over 15 years and is in charge of the robotic surgery program. His research and clinical activity are focused on Prostate (BPH and cancer). His main research programs include discovery and validation of biomarkers for high-risk prostate cancer patients treated by chemotherapy and hormonal therapies and in inflammation in prostatic benign hyperplasia patients. He teaches and has spoken on urology, robotic surgery and molecular biology of prostate cancer at Paris XII University, IRCAD, American Uologi- cal Association (AUA) meetings and European Association of Urology (EAU) meetings. He is one of the member of the Scientific Office of EAU. He wrote over 411 articles, predominantly focusing on prostate cancer, and his work has received an array of honors, such as the Crystal Matula Award from the EAU and the first prize of research from the American Urological Association (AUA).

See COI

Theo de Reijke

Theo de Reijke

Academic Medical Center, Urology

Amsterdam, Netherlands

Disease area: Prostate cancer

Biography:
Theo M. de Reijke performed his medical training at the Free University in Amsterdam and is working since 1987 as urologist at the Academic Medical Center in Amsterdam. In 2004 he successfully defended his thesis on immunotherapy for bladder cancer. Uro-oncology (prostate and bladder cancer) is his main field of interest and he has been an active member of the European Organization for Research and Treatment of Cancer – Genito Urinary group (EORTC-GU) for many years. After serving as chairman of the prostate cancer subgroup, he was elected as secretary and later as chairman of the EORTC-GU group until June 2009. In the Netherlands, he is the chairman of the prostate cancer guideline committee and he is member of the bladder cancer guideline committee. He is member of different international Urological societies (e.g. EAU, AUA, DGU), reviewer for several international journals and member of scientific boards for different journals. In 2011, he was elected as reviewer of the month for European Urology. He is (co-) author of over 100 publications in peer-reviewed journals and he made contributions to many book chapters. He organised several scientific national and international meetings and is/was coordinator of international uro-oncology trials.

See COI

Maria De Santis

Maria De Santis

Charité Medical University Hospital, Medical Oncology

Berlin, Germany

Disease area: Bladder cancer

Biography:
Maria De Santis is a medical oncologist and has recently been appointed Chair of Section for Interdisciplinary Genitourinary Cancer Medicine at the Charité University Hospital, Berlin, Germany. Dr De Santis has been an Adjunct Professor for Oncology at the Department of Urology, Medical University of Vienna, Austria since 2016. Dr De Santis is a member of several international scientific committees, including the European Society of Medical Oncology, the European Association of Urology, and the German Society for Hematology and Oncology. She also served as a scientific committee member of the American Society of Clinical Oncology for a 3 year term. She has authored multiple peer-reviewed articles in genito-urinary cancer medicine. In addition, Dr De Santis is a panel member of the European Association of Urology Scientific Office and Guidelines Board and the International Consultation on Urologic Diseases guideline groups on bladder, testicular and prostate cancer. Her research interests include prostate, bladder, renal and testicular cancer.

See COI

Guillermo De Velasco

Guillermo De Velasco

University Hospital 12 de Octubre, Medical Oncology

Madrid, Spain

Disease area: Renal Cell Carcinoma

Biography:
Guillermo de Velasco, MD PhD is a medical oncologist with special interest in genitourinary (GU) tumors. Dr. de Velasco received his medical degree from Complutense University, Madrid, Spain in 2006. In 2011, Dr. de Velasco completed his residency training in Medical Oncology at the University Hospital 12 de Octubre in Madrid, Spain. During the last two years of his fellowship, he also obtained a Master’s degree in Molecular Oncology at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain. After finishing his Oncology fellowship in Spain, Dr. de Velasco was awarded with an ESMO fellowship to work in the Genitourinary Department at Cambridge University, UK under the directorship of Professor Tim Eisen. While there, he also developed research in Christian Frezza’s Lab to explore metabolomics signatures in kidney cancer. In 2015, Dr. de Velasco was awarded with a SEOM fellowship to join the Dana-Farber/Harvard Cancer Center in Boston, MA, USA, as a research fellow with Professor Toni K. Choueiri, where he was involved in several clinical and translation investigations in the GU field. Dr. de Velasco is currently an independent clinical researcher and attending physician at University Hospital 12 de Octubre. His research focuses on understanding mechanism of response and resistance to different treatments in in renal cell carcinoma and other GU malignancies.

See COI

Stefan De Wachter

Stefan De Wachter

University Hospital Antwerp, Urology

Antwerp, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Prof. Dr. Stefan De Wachter is professor of Urology at the University Hospital of Antwerp and chairman of Urology in the academic Hospital Antwerpen. He is involved in the management of functional urology, neurourology, and reconstructive urology. In 2003, he obtained his PhD degree, for which he received the “EAU Thesis Award” in 2004. He serves as reviewer for many international urological journals, such as Neurourology and Urodynamics, Journal of Urology, European Urology, International Urogynaecology Journal, British Journal of Urology and Spinal Cord. He has published more than 120 papers in peer-reviewed journals, and presented at numerous national and international symposia and congresses.

See COI

Karel Decaestecker

Karel Decaestecker

Ghent University Hospital, Urology

Ghent, Belgium

Disease area: Bladder cancer

Biography:
Prof. Dr. Karel Decaestecker is Head of Clinic at the department of Urology at Ghent University Hospital, Belgium. He graduated magna cum laude as Master in Medicine in 2006 and completed his residency in Urology in 2012 at Ghent University Hospital. In 2012, he became Fellow of the European Board of Urology with the second highest score. On September 11th, 2015, he succesfully defended his Ph.D. on Metastasis-directed therapy for oligometastatic prostate cancer recurrence at Ghent University and is appointed as Professor Uro-Oncology at Ghent University since October 1st, 2018. He had his training in robotic surgery in 2011 in AZ Groeninge Kortrijk and OLV Aalst, Belgium. He has performed over 500 robotic procedures, mainly in the field of uro-oncology. He was trained by Prof. Dr. Abolfazl Hosseini (Karolinska University Hospital, Stockholm, Sweden) in robotic cystectomy and totally intracorporeal urinary diversion and has performed > 200 procedures, including 100 intracorporeal neobladder reconstructions. He performed the first robot-assisted kidney transplantation in Belgium in april 2016 after training at ORSI academy by Prof. Dr. Rajesh Ahlawat (New Dehli, India) and Dr. Alberto Breda (Fundacion Puigvert, Barcelona). He also performed the first European robot-assisted kidney autotransplantation in june 2017. Dr. Decaestecker is an active member of several scientific parties, including the EAU Robotic Urology Section (ERUS) Robot-assisted Kidney Transplantation (RAKT) group and the ERUS Scientific Working Group Bladder Cancer. He has recently joined the EAU Section of Transplantation Urology (ESTU) board. He is also in the Board of Directors of the BVU Scientific Summits. Dr. Decaestecker has written or colaborated in several scientific papers, mainly in the field of uro-oncology, kidney transplantation and minimal invasive surgery. He is highly involved in teaching and training medical students, residents and fellow urologists/surgeons.

See COI

Antoine Desmet

Antoine Desmet

Jules Bordet Institute, Radiation Oncology

Brussels, Belgium

Disease area: Breast cancer

Biography:
Dr Antoine Desmet has been working as a Radiation Oncologist at the Jules Bordet Institute, Brussels, Belgium since 2018. After graduating from the Catholic University of Louvain (UCL), Brussels, in 2012, he completed his residency in Radiotherapy-Oncology at Jules Bordet Institute. In 2018, he obtained his Master of Specialization in Radiotherapy-Oncology with greatest distinction (summa cum laude) and was nominated for the Dean’s Award (Université Libre de Bruxelles (ULB)). During his residency, he received training by ABRO/BeSTRO (Belgian Society of Radiation-Oncology) and completed a post-graduate training in Radioprotection. He is member of the Belgian Society of Radiation Oncology (BVRO), the European Society for Radiotherapy and Oncology (ESTRO) and lecturer at the Université Libre de Bruxelles (ULB) at the Faculty of Medicine. Dr Desmet is highly involved in teaching and training medical students and residents. He is the Radiation Oncologist in charge of the breast clinic at Jules Bordet Institute and is specialized in breast cancer, skin cancer and Intra Operative Radiotherapy (IORT).

See COI

Véronique Diéras

Véronique Diéras

Centre Eugène Marquis, Medical Oncology

Rennes-Cedex, France

Disease area: Breast cancer

Biography:
Véronique Diéras, MD, is senior medical oncologist and head of the Breast Cancer Group in the Department of Medical Oncology at the Centre Eugène Marquis in Rennes, France and former Head of Clinical Research, Department of Medical Oncology in Institut Curie, Paris, France Dr Diéras received her medical training at the University of Nantes, France, and completed residencies and further specialty training at the Hospital of Rennes and at the Institut Curie. She also earned a master’s degree in human biology at the University of Paris Saint Antoine and in oncopharmacology at the University of Paris Saint Louis-Lariboisière. She was visiting Professor at the Institute for Drug Development in San Antonio, Texas (Prof Von Hoff). Her main focus is breast cancer treatment and research and early drug development. Dr Diéras is involved in early clinical trials, breast cancer trials, and a translational research program focusing primarily on predictive factors of response to treatment. She is principal investigator in several national and international studies of breast and other cancers in adjuvant treatment and metastatic disease. Dr Diéras is a member of several societies, including the European Society of Medical Oncology (ESMO; Scientific Committee and track chair Metastatic Breast Cancer 2020), American Society of Clinical Oncology (ASCO), European Organisation for Research and Treatment of Cancer (EORTC, former member of the EORTC’s New Drug Development Program, Drug Study Group in Oncology, and Breast Group, Protocol Review Committee), the French Drug Agency, Institut National du Cancer, and UNICANCER (Breast Board, Early Clinical trials, Personalized Medicine, and former chair of the Early Clinical Trials Group). She is a participant in the European School of Oncology. Dr Diéras serves on the editorial board of Lettre du Cancérologue and as a reviewer for various oncology journals. She is author or co-author of more than 200 publications in such journals as Journal of Clinical Oncology, New England Journal of Medicine, Annals of Oncology, The Lancet Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, the British Journal of Cancer, and International Journal of Cancer.

See COI

José Luis Domínguez-Escrig

José Luis Domínguez-Escrig

Instituto Valenciano de Oncologia, Urology

Valencia, Spain

Disease area: Prostate cancer

Biography:
Dr. José Luís Domínguez-Escrig graduated in Medicine and Surgery in July1994, in Valencia, Spain, continuing his postgraduate training in the UK. Having completed his BST obtained the Membership of the Royal College of Surgeons of England in 2001 and the Fellowship of the Royal College of Surgeons in Urology, FRSC(Urol) in 2009. From 2004 to 2006 he performed his research at the prestigious Northern Institute for Cancer Research-Newcastle University, UK. On completion of his research project, he submitted the Thesis “Tyrosine Kinase and Farnesyltarnsferase Inhibitors: Potential Selective Tailored Therapeutics in Bladder Cancer” and was awarded the Degree of Doctor of Medicine in 2006. He has published in several international peer reviewed Journals and he has reviewed articles for BJU Int, Urol Oncology and the Journal of Urology and has imparted several lectures and presented at international meetings including AACR, AUA, EAU, BAUS and AEU. He returned to Spain in 2011 and he is currently working as a Consultant Urology Surgeon at the Fundación Instituto Valenciano de Oncología (I.V.O.) in Valencia, where he combines his clinical work with an active involvement in translational research, participating as PI in several Clinical Trials in prostate and bladder cancer. Since 2015 is a systematic reviewer for the EAU NMIBC Guidelines panel and also Spanish delegate to the European Board of Urology (E.B.U.) as well as, member of the F.E.B.U. examination committee. His main interests are urothelial carcinoma NMIBC and MIBC and the evaluation and development of focal therapies in Uro-oncology.

See COI

Marcus Drake

Marcus Drake

Bristol Urological Institute, Urology

Bristol, United Kingdom

Disease area: Lower Urinary Tract Dysfunction

Biography:
Marcus Drake is Consultant Surgeon at the Bristol Urological Institute, Bristol, UK, subspecialising in Female and Reconstructive Urology, Neurourology and Urodynamics. He is Senior Lecturer in Urology at the University of Bristol, and Visiting Professor in Health and Applied Sciences at the University of the West of England. He is Chief Investigator of the national randomised trial of urodynamics in male LUTS (UPSTREAM) and a study of melatonin for nocturia in MS. He was co-ordinating investigator of the multinational studies of combination therapy for male LUTS (NEPTUNE-2) and overactive bladder (BESIDE). He leads a basic science research programme in integrative neurophysiology and functional urology. He has published over 100 research papers and reviews, a book and 20 book chapters. He is Chairman of the International Continence Society’s Standardisation Steering Committee, a board member of the European School of Urology, and of the European Society of Female and Functional Urology. He is also a member of the European Association of Urology Guidelines committee for Male LUTS. In 2012, he chaired the Neurogenic Incontinence committee at the International Consultation on Incontinence and the Nocturia committee at the Consultation on Male LUTS. He is former Chairman for Urology/ Urogynaecology in the UK National Health Service’s Comprehensive Clinical Research Network. He undertook his medical training at the Universities of Cambridge and Oxford and was awarded his Doctorate Thesis by the University of Oxford.

See COI

Ignacio Duran

Ignacio Duran

Hospital Marques de Valdecilla, Medical Oncology

Santander, Spain

Disease area: Bladder cancer,Renal Cell Carcinoma

Biography:
Ignacio Durán is a medical oncologist with interests in clinical and translational research and medical education. He is the Coordinator of the Genitourinary Oncology Program at the Medical Oncology Department in Hospital Universitario Marques de Valdecilla,Santander, Spain. Dr Durán earned his medical degree in 1997 at the Universidad de Salamanca, Spain, and went on to attain his doctorate in 2005 at the Universidad Complutense, Spain, with highest commendation. Between 2004 and 2007, he completed a fellowship in drug development and genitourinary tumours at the Princess Margaret Cancer Centre in Toronto, Canada, and a master’s degree in the teaching of medicine at the University of Toronto. Dr Durán is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Spanish Society of Medical Oncology. His major research interests include genitourinary tumours and anticancer clinical drug development. He has authored numerous publications covering diverse areas of medical oncology in peer-reviewed scientific journals. Throughout his career, Dr Durán is recipient of the ASCO Foundation Merit Award, the Novartis Young Canadian Investigator Award, and the University Health Network Outstanding Research Presentation Award.

See COI

Alexandru Eniu

Alexandru Eniu

Riviera-Chablais Hospital, Medical Oncology

Vaud-Valais, Switzerland

Disease area: Breast cancer

Biography:
Dr. Alexandru Eniu is a senior medical oncologist at the Hôpital Riviera-Chablais, Vaud-Valais, Switzerland, where he took a position in January 2020 as Breast Unit Responsible and Disease Lead for Breast Cancer. He previously worked in the Department of Breast Tumours at the Cancer Institute "Ion Chiricuta" in Cluj-Napoca, Romania. He holds an MD and PhD degree in Medical Sciences, both from the University of Medicine “Iuliu Hatieganu” in Cluj-Napoca. Dr. Eniu has gained extensive experience from visits abroad. He was awarded a Mayo Foundation Visiting Clinician Scholarship at the Mayo Breast Cancer Clinic in Jacksonville, Florida and has been a visiting clinician at the MD Anderson Cancer Center in Houston, Texas and the Memorial Sloan Kettering Cancer Center in New York. He did a fellowship at the European Institute of Oncology in Milan, Italy. As an active member of both national and international societies, Alexandru Eniu holds positions in various committees. In 2018, he was appointed Deputy Scientific Director of the European School of Oncology after serving for several years as coordinator for the ESO Eastern Europe and Balkan Region Program. Within ESMO, he chaired the ESMO Global Policy Committee, and between 2014-2018 he was a member of the ESMO Executive Board, leading several initiatives tackling disparities in cancer outcomes across Europe and the world. Within ASCO, he served as chairman of the ASCO International Affairs Committee. Furthermore, he is a member of the editorial board of several oncology journals, including Annals of Oncology. He participated in the process of developing international and national guidelines for the management of cancer patients, serving as the Co-Chair of the Treatment and Allocation of resources Panel of the Breast Health Global Initiative and as panel member of the Advanced Breast Cancer (ABC3 and ABC4) International Consensus Conference. Dr. Eniu wrote 6 book chapters and more than 80 articles in international peer-reviewed journals within his specialty of breast cancer.

See COI

Karel Everaert

Karel Everaert

Ghent University Hospital, Urology

Ghent, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Karel Everaert graduated in 1988 from the University of Ghent as Medical Doctor. Between 1988 and 1993 he was a training resident at several national and international hospitals. Since 1993 he is responsible for Neuro-urology, incontinence, urodynamics and male infertility in the Department of Urology, UZ Ghent. He obtained his Ph.D in 1999, with a thesis on tubular proteinuria in urinary tract infection, vesico ureteral reflux and hydronephrosis. In 2001 he was appointed Full Professor in Neuro-Urology. He has attended numerous postgraduate training courses and was involved in teaching activities in Belgium and abroad. Prof. Everaert is Fellow of the European Board of Urology. He is a respected member of several urological societies. He’s founding member of PELVIRED and board member of the BVU. Prof. Everaert is author of more than 40 articles in international journals. He is co-author of several textbooks in Urology. He has given more than 50 presentations at national and international congresses and was involved in the organisation of numerous meetings. He received several awards for his research activities.

See COI

Valérie Fonteyne

Valérie Fonteyne

Ghent University Hospital, Radiotherapy

Ghent, Belgium

Disease area: Prostate cancer,Bladder cancer

Biography:
Dr Valérie Fonteyne is a staff member of the Department of Radiotherapy-Oncology at the Ghent University Hospital, Ghent, Belgium since 2003. Her research interests include urological tumours, pain management and stereotactic body radiation therapy. Dr Fonteyne graduated in Medicine at the Ghent University Hospital in 2003. She received training in Radiotherapy-Oncology until 2010. She completed a post-graduate training in Radioprotection in 2003 and in Biostatistics in 2006. In 2010, she obtained her PhD which was entitled ‘Intensity-modulated radiotherapy and arc therapy for prostate cancer: clinical results and new perspectives’. She is member of the Belgian Society of Radiation Oncology (BVRO), the European Society for Radiotherapy and Oncology (ESTRO) and the European Association of Urology (EAU). She is teacher of the ESTRO Prostate course. Dr Fonteyne (co-)authored more than 85 publications and was co-author of 2 book chapters. She participated in ‘Silico clinical trial in lung, prostate and head cancer, comparing photons, protons and C-ion therapy treatment: a multicentre planning study based on a reference dataset of patients’.

See COI

Pierfrancesco Franco

Pierfrancesco Franco

University Hospital 'Maggiore della Carita', Radiation Oncology

Novara, Italy

Disease area: Breast cancer

Biography:
Pierfrancesco Franco is currently Associate Professor at the Department of Translational Medicine, University of Eastern Piedmont and Clinical Consultant at University Hospital 'Maggiore della Carita', Novara, Italy. Pierfrancesco works on research in Radiation Oncology, focusing on breast cancer, gastrointestinal malignancies, head and neck. He is involved in cancer education and interested in research on professional well-being in oncology.

See COI

Dorota Gabryś

Dorota Gabryś

MSC National Research and Institute of Oncology, Radiation Oncology

Gliwice, Poland

Disease area: Breast cancer

Biography:
Dorota Gabryś is a Radiation Oncologist working at Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO) in Gliwice, Poland as an Assistant Professor. She obtained her MSc in Radiation Biology at University College London, UK, before earning her MD and PhD in Radiation Oncology. She performed research as part of the Tumour Microcirculation Group at the Gray Cancer Institute in London, UK, at the Technical University of Dresden Medical School, and the PET Center Dresden-Rossendorf at the Research Center Dresden-Rossendorf, Germany. Her research programme as a Radiation Oncologist is dedicated to providing the best breast cancer radiotherapy in patients treated in postoperative settings as well as in advanced inoperable cases with and without hyperthermia. She also performed investigations into the radiation-induced heart disease in breast cancer patients as well as in animal studies. Moreover, her research interest is in improving outcomes for patients with metastatic disease treated with stereotactic cranial and extracranial radiotherapy using CyberKnife, Edge, TrueBeam and tomotherapy. She likes difficult cases, and is therefore engaged in re-irradiation and multiple re-irradiation in variable localisations. Dr. Gabryś is a member of the Clinical Committee of the European Society for Therapeutic Radiation Oncology (ESTRO), as well as the Polish societies PTO, PTRO, PTBR.

See COI

Giorgio Gandaglia

Giorgio Gandaglia

Ospedale Vita-Salute San Raffaele, Urology

Milan, Italy

Disease area: Prostate cancer

Biography:
Giorgio Gandaglia is a Urologist at the Department of Urology, San Raffaele Hospital, Milan, Italy. He earned his MD in 2011 at the Vita-Salute University, Milan where he also pursued residency. He completed a Research Fellowship in Urologic Oncology at the Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada under the supervision of Prof. Pierre I. Karakiewicz and a fellowship at the OLV Robotic Surgery Institute, Aalst, Belgium, under the supervision of Prof. Alexandre Mottrie. Dr. Gandaglia has written and coauthored more than 220 peer-reviewed journal articles (PubMed) and his H-Index is 27 (Scopus). He serves as Reviewer for the main urologic journals and in the year 2015 he was selected as Reviewer of the Year by European Urology. Dr. Gandaglia is a member of the EAU Young Academic Urologists Working Party – Prostate Cancer since March 2016. Moreover, Dr. Gandaglia is a member of the Scientific Committee of the Italian Society of Urology (SIU). His main clinical and research interests are focused on prostate cancer, benign prostatic enlargement and bladder cancer with a particular focus on minimally invasive techniques and robotic surgery.

See COI

Joseph Gligorov

Joseph Gligorov

University Institute of Cancerology AP-HP Sorbonne University, Medical Oncology

Paris, France

Disease area: Breast cancer

Biography:
Joseph Gligorov is Professor of Medical Oncology at the University of the Sorbonne and Medical Practitioner in the Department of Medical Oncology at Tenon Hospital (AP-HP), Paris, France. He is currently the executive director of the University Institute of Cancer (AP-HP) Sorbonne University, grouping treatment, education and research on cancer within a network of 7 university hospitals and the different departments of Sorbonne University (Sciences and Humanities). This structure takes care of more than 15,000 cancer patients each year (including more than 10,000 newly diagnosed per year) in all areas of hematology and oncology and at all ages from pediatrics to geriatrics. Regarding his clinical activity, he is co-chairing the Breast Cancer Expert Center at Tenon Hospital and is mainly involved in breast cancer treatment. His clinical and translational research activity is focused on breast cancer predictive and prognostic markers. He is involved in clinical research and he is member of several steering committees and independent data monitoring committees (IDMC). He is also part of the INSERM U938 team “Cancer biology and treatments”, mainly involved in the field of breast cancer and its endocrine dependence. Joseph Gligorov is vice-president of the French National College of Cancerology Education and his educational activity is focused primarily on student and resident oncology education. At Sorbonne University, he is developing new educational programs for specialized nurses in oncology and for patients in partnership with the “patient’s university”. Prof Joseph Gligorov is in charge of the Nice – Saint-Paul-de-Vence breast cancer conference and treatment guidelines, and is a member of different national working groups devoted to cancer treatment strategies. He is also co-founder and president of the Mediterranean Association for Radiotherapy Oncology and Medical Oncology (AROMe) devoted to cancer patients care improvement, access to innovations and oncology education in emerging countries around the Mediterranean area. He is a member of several editorial boards, advisory committees and national and international scientific societies. He is also an ESMO and ESO core faculty member and is one of the members of the ESO-ESMO Metastatic Breast Cancer Task Force. Joseph Gligorov has published more than 300 journal articles (among them more than half Medline indexed) and participated in the editing and writing of several books.

See COI

Michael Gnant

Michael Gnant

Medical University of Vienna, Surgical Oncology

Vienna, Austria

Disease area: Breast cancer

Biography:
Dr Michael Gnant is Full Professor of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast & Colorectal Cancer Study Group. He is co-chairing the renowned St Gallen Consensus Panel for Early Breast Cancer since 2015. Dr Gnant graduated in medicine in Vienna (1988) and subsequently specialised in surgery (1994) and surgical oncology. He also worked as a Visiting Scientist at the National Cancer Institute, National Institutes of Health, Bethesda, USA (1997–1999). Dr Gnant’s research interests include several fields of surgical oncology, in particular breast and pancreatic cancer, immunotherapy, bone-targeted treatment for tumour micrometastases, and pathway-directed therapies such as mTOR and CDK4/6 inhibition. He has been the Principal Investigator of many clinical trials in these fields. The author of more than 450 original peer-reviewed papers with an impact factor of 3,400 and an h-index of 66, Dr Gnant has presented over 1,000 lectures at national and international meetings. He is the recipient of multiple awards including the prestigious Claudia von Schilling Prize from the Medical University of Hannover, and a Corresponding Member of the Austrian Academy of Sciences. Dr Gnant is involved in many scientific societies including ASCO, AACR, ACS, Breast International Group (BIG), EORTC, ESSO, EUSOMA and UICC. He served as an executive board member of BIG, is an independent reviewer and IDMC member for the EORTC, UICC and other international bodies, and is a scientific reviewer and process evaluator for the European Union. Dr Gnant is also Editor-in-Chief of BREAST CARE, and editorial board member and reviewer for many top-tier peer-reviewed journals including The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, and Annals of Oncology.

See COI

Francisco Gomez-Veiga

Francisco Gomez-Veiga

University Hospital of Salamanca, Urology

Salamanca, Spain

Disease area: Prostate cancer,Renal Cell Carcinoma

Biography:
Francisco Gómez-Veiga studied Medicine at the University of Santiago de Compostela, Spain, where he obtained his Degree in Medicine. During 1987-1992, he received his internship training in Urology at the A Coruña University Hospital, where he obtained his PhD degree. His main activities were focussed on kidney transplant and uro-oncology. Currently, he is Head of the Urology Department and Kidney Transplant, Head of the Grupo de Investigación Traslacional de Urología (GITUR) and Professor of Medicine at the University Hospital of Salamanca, Spain. He received training in several European and US hospitals on different techniques and aspects of kidney transplant and oncology. Francisco Gómez-Veiga has been coordinator and member of the steering committee in different clinical trials (CT). He has wide experience in more than 50 CT, mainly focussing on uro-oncology. Nowadays, he is the main investigator in 20 ongoing Phase II-III CT on prostate cancer, from local to castrate-resistant prostate cancer, bladder cancer, kidney tumours and benign prostatic hyperplasia. His team is also running different lines on basic research of prostate and bladder cancer. He is co-author of more than 120 published national and international articles and 30 published books related to kidney transplant and uro-oncology. He is a peer reviewer for urological journals such as Actas Españolas de Urología, Archivos Españoles de Urología, Urology International, Canadian Urological Association Journal and European Urology Supplements, and is an active member of the Scientific Committee of Spanish Guidelines for Prostate Cancer, the Spanish Urological Association (AEU), the European Board Urology (EBU sub-specialty), the Scientific Committee of the European Urological Association (EAU), the American Urological Association (AUA), the Genito Urinary Cancer Group “EORTC” and is international reviewer for the French National Cancer Institute. He received awards from the Spanish and European Urological Associations and Société Internationale d´Urologie in recognition for outstanding publications and presentations.

See COI

Paolo Gontero

Paolo Gontero

University of Piemonte Orientale, Urology

Novara, Italy

Disease area: Prostate cancer,Bladder cancer

Biography:
Paolo Gontero is Associate Professor of Urology at the University of Studies of Torino, Division of Urology, San Giovanni Battista Hospital, Torino, Italy. He is currently Director of a Second Level Master Degree Course in Prostate Oncology at the University of Torino. His main clinical interests are Oncology Urology Surgery, Laparoscopic and Robotic kidney and prostate oncological surgery and Reconstructive Urology. He has authored and co-authored more than 150 publications on international journals. His main research interests pertains the development of new treatment modalities for non-muscle invasive bladder cancer and prostate cancer. He is Scientific Director of the “Torino Prostate Project”, a multidisciplinary clinical and research working group in the field of prostate cancer. He is involved in international trials and working groups on the development of new diagnostic and therapeutic modalities for prostate cancer and on the assessment of surgery in high risk prostate cancer. He is chairmen of the Course on Small Renal Masses at the European School of Urology and holds active membership with EORTC-GU, ISSECAM-EMPACT and eGUS. He has co-authored several book chapters and edited several books, including the latest Problem Based Urology, Springer 2013, awarded by the BMA Book Award as highly commended n surgical specialties.

See COI

Helena Gouveia (Associate)

Helena Gouveia (Associate)

Champalimaud Foundation/Champalimaud Clinical Center, Medical Oncology

Lisbon, Portugal

Disease area: Breast cancer

Biography:
Helena S. Gouveia is a young Breast Medical Oncologist working at the Breast Unit of the Champalimaud Centre for the Unkown in Lisbon, Portugal for the last 3 years. Participating in both translational and clinical research, she is keen on survivorship issues which commonly affect breast cancer patients. She strives to practice evidence-based medicine, ensuring all patients reach the best possible care. As a member of ESMO, ASCO and other research societies alike, she values continuous learning and helping her peers achieve optimal care for breast cancer patients worldwide, by following and adapting existing oncology guidelines.

See COI

Alexander Govorov

Alexander Govorov

Moscow State Medical Stomatological University, Urology

Moscow, Russia

Disease area: Prostate cancer

Biography:
After graduating from Medical School in 1998, Alexander Govorov started his residency in Urology at the Department of Urology of MSMSU in Russia. In 2001 he did a Clinical Fellowship with Prof. L. Boccon-Gibod at the Department of Urology of the Bichat Hospital in Paris. In 2002 he obtained his PhD from MSMSU. He accepted a position of Associate Professor of Urology at the Urology Department of the Moscow State University of Medicine and Dentistry (Chairman - Prof. D. Pushkar) in 2003, and became Professor of Urology in 2017. He is board certified for Urology and Oncology. Dr. Govorov is a member of the EAU, AUA, SIU and the Russian Associations of Urology and Oncology and was a Board Member of the European Society of Oncological Urology (ESOU) from 2006 to 2017. In 2017-2018 – EAU Prostate Cancer Guidelines panel member. In 2006 he has won the Russian award for “The valuable contribution to Russian Urology”. Alexander Govorov’s primary clinical interest concentrates on operative and conservative uro-oncology, and particulary on prostate biopsy and minimally-invasive treatment of prostate cancer. In 2003, he was the first HIFU specialist in Russia and in 2010 he performed the first cryoablation of the prostate in Russia. He has published in several medical journals, wrote chapters of books, participated in many academic and clinical trials and he presented at numerous national and international congresses.

See COI

Martine Granek-Catarivas

Martine Granek-Catarivas

Clalit Health Services, Tel Aviv University & EURACT, Family Medicine

Sharon-Shomron District, Israel

Disease area: COVID-19

Biography:
Martine Granek-Catarivas is Head to one the departments of Family Medicine, Tel Aviv University (Israel), at Clalit Health Services. Born in France, she started medical school in Paris and completed her studies at Tel Aviv University. Dr. Granek-Catarivas completed her training in Family Medicine at Tel Aviv University and soon started teaching medical students and residents. While living for five years in China, she joined the Hong Kong College of General Practitioners and Beijing Capital University of Medical Sciences, teaching and examining students and residents, and mainly focusing on Faculty Training in Family Medicine throughout China on behalf of WONCA. Later, she contributed to the development of Balint Groups in China. Since her return to Israel, she developed a clerkship in Ambulatory Medicine for New York program at Sackler Faculty of Medicine and led for 10 years the faculty development program of the Department of Family Medicine at Tel Aviv University. For 8 years she was Head of the Israel Society of Teachers in Family Medicine, and since 2017 she represents Israel at EURACT Council. Furthermore, she is an active member in various committees of the Medical Council at Israel Medical Association. Her activities at the department of Family Medicine include teaching of undergraduate medical students, training of post graduate residents and stagiaires on elective in Family Medicine and training of tutors and trainers. She is also active in CME/CPD for primary care physicians in Sharon Shomron district. Dr. Granek-Catarivas keeps working half time as a Family Physician providing acute and chronic care for patients of all age groups, ethnic and cultural backgrounds. Her main areas of teaching and research are Faculty Development, Teachers training, Patient-Centered Medicine, Communication skills and Balint Groups.

See COI

Charlotte H Graugaard-Jensen

Charlotte H Graugaard-Jensen

Aarhus University Hospital, Urology

Aarhus, Denmark

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr. Graugaard-Jensen is Associate Professor of Urology at the University of Aarhus, Denmark. She studied medicine in Aarhus, where she completed her PhD thesis in 2008 on diurnal regulation of urine production. She conducted her residency in Viborg and Aarhus from 2008-2014, and is now working primarily on functional urology in the pelvic floor section at the Department of Urology, Aarhus University Hospital. Dr. Graugaard-Jensen is an active member of the Danish Urological Association and The Danish Urogynecologic association, in which she has been the treasurer for six years (2010-2016). She is chairwoman of the Nordic group on Lower Urinary Tract Dysfunction (2016-). She participates in a Danish Expert group set by the Health authorities to make a National Recommendation list/guideline to GPs treating lower urinary tract dysfunction. In 2016 she was appointed to the Regional Committee on Health Research ethics. Dr. Graugaard-Jensen has published 10 original scientific articles and 5 book chapters.

See COI

Petros Grivas

Petros Grivas

University of Washington, Medical Oncology

Seattle, USA

Disease area: Bladder cancer,Renal Cell Carcinoma

Biography:
Dr. Petros Grivas is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the new Clinical Director of the Genitourinary Cancers Program at University of Washington and Associate Professor in the Dept. of Medicine, Division of Oncology. He is also an Associate Member in the Fred Hutchinson Cancer Research Center. He was recruited from the Cleveland Clinic, Cleveland, OH, where he was leading the bladder/urothelial cancer program, pursuing clinical and translational research, organizing community outreach events, mentoring trainees, and seeing patients with GU cancers. Dr. Grivas completed his training at the University of Patras Medical School and took his M.D. degree in 2005; he then pursued Ph.D. in Medical Oncology under the mentorship of key academic faculty and defended his thesis successfully in late 2008. He completed his Residency in Internal Medicine at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia, USA) in 2010. He then completed his Fellowship in Hematology/Oncology at University of Michigan (Ann Arbor, USA) in 2013. He stayed there as Clinical Lecturer for another year before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland, USA). He has had main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer, and is considered a key opinion thought leader and international expert, giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel, transformative and important research. He is dedicated to efficient, personalized and outstanding patient care and believes in optimal patient-physician relationship, mentorship and community outreach.

See COI

Valentina Guarneri

Valentina Guarneri

University of Padova, Medical Oncology

Padova, Italy

Disease area: Breast cancer

Biography:
Valentina Guarneri is Associate Professor of Oncology at the University of Padova and head of the Network Clinical Research Unit at the Oncology Institute Veneto in Padova, Italy, where she is Vice-Director of the Specialty Programme in Medical Oncology. From 2015 to 2018, she was member of the Research Committee of the Italian Ministry of Health. Dr. Guarneri completed her fellowship in Oncology in 2003 and obtained her PhD degree in Clinical and Experimental Oncology in 2007. In 2005, she completed a research experience at the Department of Breast Medical Oncology, MD Anderson Cancer Center in Houston, Texas, where she also was Visiting Assistant Professor in 2009. In 2005, she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia in Modena, Italy, where she also chaired the Breast Unit from 2011 to 2013. Dr. Guarneri is a member of the ESMO Fellowship and Award Committee and of the Oncology Pro Working Group, and was a long-standing member of the ESMO Young Oncologists Committee (YOC). She is also a founder member of the Women for Oncology Italy initiative (a national spin-off of the ESMO initiative). She is in the editorial review board of several international journals, including The Lancet Oncology, Annals of Oncology, Clinical Cancer Research, The Oncologist and Clinical Breast Cancer. Her research interest is mainly focused on clinical and translational research for breast cancer patients. She published more than 140 papers in peer-reviewed journals (JCR-ISI WEB 2018 Total Impact Factor: 840).

See COI

Alexander Haese

Alexander Haese

Martini-Klinik Prostate Cancer Center, University Clinic Eppendorf, Urology

Hamburg, Germany

Disease area: Prostate cancer

Biography:
Still to be added

See COI

Shaista Hafeez

Shaista Hafeez

The Royal Marsden NHS Foundation Trust, Clinical Oncology

London, United Kingdom

Disease area: Bladder cancer

Biography:
Dr Shaista Hafeez is a Clinical Oncology Consultant at The Royal Marsden NHS Foundation Trust and a Clinician Scientist at The Institute of Cancer Research, London. Dr Hafeez graduated from Imperial College School of Medicine at St. Mary’s, London. She completed specialist clinical oncology training in London. In 2013 she was awarded a Cancer Research UK PhD Fellowship and undertook a period of research at The Institute of Cancer Research and The Royal Marsden Hospital investigating functional Magnetic Resonance Imaging (MRI) and advanced image guided adaptive radiotherapy techniques in bladder cancer. Dr Hafeez received several awards for this work including The Royal College of Radiologists Ross Award, The National Cancer Research Institute (NCRI) Prize, and in 2017 she was awarded The Chairman’s Prize, for her PhD at The Institute of Cancer Research. Dr Hafeez was appointed jointly as Consultant Clinical Oncologist and Clinician Scientist in the Urology Unit and Division of Radiotherapy and Imaging at The Royal Marsden and The Institute of Cancer Research in 2017. She specialises in radiotherapy and systemic treatment of patients with urological cancers in particular those with bladder cancer. Her on-going research aims to improve patient outcomes by developing individualised approaches to radiotherapy delivery.

See COI

Karena Hanley

Karena Hanley

Irish College of General Practitioners, Family Medicine

Dublin, Ireland

Disease area: COVID-19

Biography:
With a basic medical degree in 1987 from University College, Dublin, Dr. Karena Hanley obtained MIGP and MRCGP in 1992. Further qualifications include a Master’s in Family Medicine in 2000 and FRCGP in 2008. Karena has 30 years’ experience of running a busy GP practice, and has been a medical educator since 2000. Her research interests are varied with a dozen peer reviewed publications including four in the BJGP. She has published diverse topics such as therapeutics, immediate care, the clinical presentation of vertigo and several medical education publications. Karena is a former Provost of the RCGP Ireland faculty. She has held a variety of officer posts for the Irish College of General Practitioners, including ICGP Regional Research Adviser, and Chair of a number of college committees. From 2016-2020 Karena served as ICGP National Director of GP training. She is now Lead of Innovation and Development in GP training.

See COI

Nadia Harbeck

Nadia Harbeck

University of Munich, Obstetrics & Gynaecology

Munich, Germany

Disease area: Breast cancer

Biography:
Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Department of OB&GYN at the University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005-2009, she was an assistant professor and head of Conservative Senology at TUM and from 2009-2011, she was head of the Breast Center at the University of Cologne, Germany. Professor Harbeck is a member of the expert panel issuing the yearly updated evidence based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is scientific director of the West German Study Group (www.wsg-online.com). From 2009-2015, she served on the executive board of the EORTC as the chair of the translational research division. Professor Harbeck is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com). Professor Harbeck has authored more than 470 papers in peer-reviewed journals (cumulative impact factor >3000; h-index 80) and is coordinating editor-in-chief of Breast Care (Karger Publishers). For her clinical translational research, she has received numerous awards, including the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract submitted. She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen).

Karin Haustermans

Karin Haustermans

University Hospital Gasthuisberg, Radiation Oncology

Leuven, Belgium

Disease area: Prostate cancer

Biography:
Karin Haustermans graduated in 1987 as Doctor in Medicine, Surgery and Obstetrics (MD) at the Catholic University of Leuven (KU Leuven) in Belgium. In 1993, she completed her training and qualification in Radiation Oncology. After a research fellowship at the Laboratory of Experimental Radiotherapy at the KU Leuven, she obtained her PhD in Medical Sciences for which she received in 1996 the ESTRO-VARIAN Clinical Research Award. Thereafter she spent four years as a staff member at the Netherlands Cancer Institute in Amsterdam. Currently, Karin Haustermans is Medical Director of Protontherapy ParTICLe and Secretary of the Leuven Cancer Institute at the University Hospital Gasthuisberg (Belgium). She is Full Professor at the KU Leuven. She is specialized in GI and GU oncology and has a part time appointment as a clinical research fellow of the Research Foundation Flanders. She is a member of several (inter)national scientific organizations. From 2006 to 2009 she held the Chair of the EORTC Radiation Oncology Group and from 2009 until 2015 she was Chair of the Quality Assurance Committee of EORTC. She is also heavily involved in the Belgian Cancer Registry as a member of the board and Chair of the Coordination Council. In 2010 she was awarded the ESTRO Breur medal in recognition of her major contribution to European Radiotherapy. From 2011 onwards she was appointed as a member of the Belgian Royal Academy of Medicine and in 2015 she became a fellow of the European Academy of Cancer Sciences. Since 2016 she is clinical editor of Radiotherapy & Oncology. Karin Haustermans has 289 peer reviewed publications (h-index: 51).

See COI

Simon Hawlina

Simon Hawlina

MD Medicina, Urology

Ljubliana, Slovenia

Disease area: Lower Urinary Tract Dysfunction

Biography:
Asist. Prof. Simon Hawlina passed his internship examination in Portugal in 2002. He worked as a medical doctor in Papua New Guinea from May to September 2003 and is a Urology Consultant since 2010. He completed his sub-specialization in laparoscopy under Prof. Renaud Bollens in Belgium in 2014 and his sub-specialization in robotic & laparoscopic surgery under Prof. Justin Vale in England in 2016. In 2018, he received his licence to work with the daVinci Xi - console as a surgeon. He is well-trained in open and laparoscopic surgery and diagnostic procedures in urology. He currently works as an assistant professor at the Medical Faculty of Ljubljana. He is also the leader of a research project team in the Clinical Centre Ljubljana and part of several other research project teams there. He is the director of the Robotic Assisted Laparoscopy Devision at the University Clinical Centre Ljubljana as of 2018. He received the Karl Storz Third prize: “Complications of en-block resection of bladder tumors with bipolar hook cutting electrode” in 2016.

See COI

John Heesakkers

John Heesakkers

University Medical Centre Nijmegen, Urology

Nijmegen, Netherlands

Disease area: Lower Urinary Tract Dysfunction

Biography:
John Heesakkers studied Medicine at the Radboud University of Nijmegen. He started his training in Urology in 1993 at the University Hospital Maastricht. In 1997 he successfully defended his thesis titled: ‘Dynamic Urinary Graciloplasty’ at the University of Maastricht. Since 2000 he is a full time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He is heading the Unit of Functional Urology and Neurourology. He chairs the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology. John Heesakkers is an active member of the AUA, EAU, ICS and SUFU. He is a faculty member of the European School of Urology and of the Scientific Congres Organization of the EAU. Since 2008 he is a principal investigator for the Nijmegen Centre for Molecular Life Sciences. He is reviewer of several major Urologic Scientific journals. He is the author of more than 125 peer-reviewed papers and more than 10 book-chapters and books on urological topics.

See COI

Anna Hester (Associate)

Anna Hester (Associate)

University of Munich, Obstetrics and Gynecology

Munich, Germany

Disease area: Breast cancer

Biography:
Anna Hester is a gynecologist at the Department of Obstetrics and Gynecology at the University Hospital Munich (LMU), Germany. She obtained her medical degree from the University of Wuerzburg and holds an additional Master of Science degree in experimental medicine. She obtained her specialist degree (OB&GYN) at the University of Munich (LMU). The fields of interest of Dr. Hester include conservative gyneco-oncology and especially predictive markers and the role of the immune system in breast cancer. She has (co-)authored 24 peer-reviewed publications.

See COI

Sebastian Hofbauer

Sebastian Hofbauer

Charité Medical University Hospital, Urology

Berlin, Germany

Disease area: Bladder cancer

Biography:
Sebastian Hofbauer is a Urologist at the Department of Urology at the University Hospital of Berlin (Charité), Germany. After graduating from the Medical University of Vienna, Austria in 2012, he completed a Research Fellowship and started a Ph.D. program in Urologic Oncology at the Department of Urology at the Medical University of Vienna under the supervision of Prof. Tobias Klatte and Prof. Shahrokh F. Shariat, followed by a residency in 2013 at the same institution. In 2015, he moved to Berlin to continue his residency at the Department of Urology at the University Hospital Berlin. He has written and coauthored more than 30 peer-reviewed journal articles. He serves as reviewer for European Urology Focus. His main clinical and research interests are focused on prostate and bladder cancer.

See COI

Milan Hora

Milan Hora

University Hospital Pilsen, Urology

Pilsen, Czech Republic

Disease area: Renal Cell Carcinoma

Biography:
Milan Hora, Professor of Urology, was born in 1967 in Pilsen, Czech Republic. He has been an employee of the Department of Urology, University Hospital Pilsen and the Faculty of Medicine at Charles University since 1991, where he has been the Head of the Department since 2003. Dr Hora is board certified in Urology (1997) and Onco-urology (2016) and received his honorary degree at the Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. His professional training includes visits to international urological departments at AKH Wien, Austria; The Cleveland Clinic Foundation, Ohio, USA; Institut Mutualiste Montsouris, Paris, France; Mainz, Germany; Wales, Cardiff, UK, and the General University Teaching Hospital, Prague, Czech Republic. His topics of interest are mainly focussed on onco-urology (especially renal tumours and penile cancer), laparoscopy, robotic surgery and andrology. Dr Hora is vice-chairman of the Czech Urological Society, chairman of the Accreditation committee of Czech Health Ministry for Urology and Onco-urology, secretary of the Local Ethical Committee of University Hospital in Pilsen, part of the working group on Kidney Cancer of the European Association of Urology (EAU) Guidelines Office, and member of the European Board of Urology (EBU). He is editor-in-chief of the Czech Urology journal and member of the editorial board of the World Journal of Urology. In addition, he is member of the European Urology Residents Education Programme (EUREP) faculty. Milan Hora has (co-)authored 4 textbooks, 6 textbook chapters, 344 peer-reviewed publications and numerous abstracts and presentations.

See COI

User avatar

Jens Huober

University of Ulm, Medical Oncology

Ulm, Germany

Disease area: Breast cancer

Biography:
To be added

Jacques Irani

Jacques Irani

Hôpital Bicêtre, Urology

Le Kremlin-Bicêtre, France

Disease area: Bladder cancer

Biography:
Jacques Irani studied medicine and received his PhD in clinical epidemiology and statistics. He qualified in Urological Oncology at Poitiers University Hospital. Currently, he is Professor at Paris-Sud University and head of the department of Urology at Bicetre University Hospital. His main research interests are uro-oncology. Prof. Irani is member of several national and international associations and societies. He held the posts of chairman of the French Bladder Uro-Oncological committee (CC-AFU) and member of the British Journal of Urology International (BJUI) executive board committee. He was until 2015 vice-chairman of the European Association of Urology Guidelines Committee Board. Prof. Irani is also member of several Editorial boards, including European Urology. He published over 250 publications in both national and international journals.

See COI

Aino Fianu Jonasson

Aino Fianu Jonasson

Karolinska University Hospital Huddinge, Urogynaecology

Stockholm, Sweden

Disease area: Lower Urinary Tract Dysfunction

Biography:
Aino Fianu Jonasson specialised in urogynaecology and is responsible for the Women’s Health Department at the Karolinska University Hospital Huddinge. She was registered as a physician with the National Board of Health on 21 February 1986 and became a specialist in Obstetrics and Gynaecology on 30 September 1990. She has been director of studies and was responsible for teaching medical students from 1996 until 2009. She has also been training junior doctors and undertaking clinical research. Aino Fianu Jonasson was awarded the KI’s pedagogical price in 2006 for excellent leadership and outstanding skills in developing the medical educational programs. Her research in women’s health are: treatment of postmenopausal women with urogenital atrophy, female urinary incontinence, overactive bladder and nocturia.

See COI

Rob Jones

Rob Jones

Beatson West of Scotland Cancer Centre, Medical Oncology

Glasgow, United Kingdom

Disease area: Bladder cancer

Biography:
Rob is Professor of Clinical Cancer Research at the University of Glasgow and a consultant at the Beatson West of Scotland Cancer Centre. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials. He is vice-chair of the UK National Cancer Research Institute Bladder and Kidney Clinical Studies Group (CSG), he also chairs the Advanced Disease Subgroup of the Prostate Cancer CSG. He is director of the CR-UK Clinical Trials Unit in Glasgow.

See COI

Orit Kaidar-Person

Orit Kaidar-Person

Sheba Medical Center, Radiation Oncology

Ramat Gan, Israel

Disease area: Breast cancer

Biography:
Dr. Kaidar-Person trained as a Radiation Oncologist at Rambam Medical Center in Haifa, Israel, between 2009 – 2014. After completing residency, she obtained a clinical fellowship in Radiation Oncology at the University of North Carolina in Chapel Hill, North Carolina, USA. There, she worked with well-known radiation oncologists, including Dr. Larry Marks. After completing her fellowship, Dr. Kaidar-Person served as the Head of Central Nervous System Radiation Oncology at Rambam Medical Center. Recently she was appointed the Head of the Breast Cancer Radiation Oncology Unit at Sheba Medical Center in Ramat Gan, which is considered one of the leading Hospitals in Israel. Dr. Kaidar-Person is involved in numerous research and clinical studies mainly in Breast and Central Nervous System. She is an active member of the Radiation Oncology Group (ROG) of the EORTC. From 2012 to 2018, she served as the first Chair of the Young Radiation Oncologists Group (YROG), a working party within the ROG-EORTC devoted to involving young oncologists in clinical research, and was part of the EORTC-ECI program. She is also involved in translational research and worked alongside Prof. Yuval Shaked from the Cancer Research Laboratory of the Bruce Rappaport Faculty of Medicine, studying the interplay between host and tumor cells following anti-cancer therapy. Recently, Dr. Kaidar-Person started a PhD project within the School for Oncology & Developmental Biology (GROW) at Maastricht University in the Netherlands, focusing on postmastectomy chest wall recurrences as part of a project by an international expert working group to improve the outcome of these patients. She feels inspired and fortunate to have four outstanding PhD mentors: Liesbeth Boersma, Birgitte Offersen, Philip Poortmans and Dirk de Ruysscher.

See COI

Ashish Kamat

Ashish Kamat

University of Texas - MD Anderson Cancer Center, Urology

Houston, USA

Disease area: Bladder cancer

Biography:
Prof. Ashish M. Kamat is Professor of Urologic Oncology and Cancer Research at M.D. Anderson Cancer Center; Associate Head of the Cancer Center, Reliance Foundation Hospital in Mumbai, and President of the International Bladder Cancer Group (IBCG). He is Associate Editor for European Urology Oncology, served as the Director of the MD Anderson Urologic Oncology Fellowship from 2005-2016 and is a graduate of the AUA Leadership Program. Prof. Kamat’s focus in urologic oncology is on bladder cancer, especially immunotherapy and organ sparing therapies, and he maintains an active research portfolio in this area. His research laboratory focuses on identifying and developing predictive markers of response to therapy, and research into mechanisms of inducible cancer stem cells. These findings have been published in high impact journals and he has over 275 publications to his credit. In addition, Prof. Kamat has won the ‘Compassionate Doctor Award’ from patient groups.

See COI

Vincent Khoo

Vincent Khoo

The Royal Marsden NHS Foundation Trust, Clinical Oncology

London, United Kingdom

Disease area: Prostate cancer

Biography:
Vincent Khoo is a Clinical Oncologist at Royal Marsden Hospital, Honorary Consultant at St George’s Hospital and Honorary Senior Lecturer at Institute of Cancer Research, London University. He was previously Head of Department of Clinical Oncology Royal Marsden. He is Adjunct Professor, Department of Medical Imaging and Radiation, Monash University and Honorary Associate Professor, Department of Medicine, Melbourne University and Austin Health. He specialises in urological cancers with interests in systemic Clinical Trials, combination treatments, multi-modality imaging, and technical radiotherapy from stereotactic to image guided intensity modulated and adaptive radiotherapy. He has published over 200 papers. He is member of several national/international committees including UK NCRI Clinical-Translational Radiotherapy, UK NCRN Prostate, Penile, and Kidney Clinical Studies Groups, ESTRO, ECCO.

See COI

User avatar

Jon Kindblom

Sahlgrenska University Hospital, Clinical Oncology

Göteborg, Sweden

Disease area: Prostate cancer

Biography:
Dr Jon Kindblom is consultant at the Department of Oncology, Sahlgrenska University Hospital in Gothenburg, Sweden. He is also a researcher and lecturer at the Sahlgrenska Academy, Gothenburg University. Dr Kindblom obtained his medical degree in 1997 and his PhD in 2003, both from Sahlgrenska Academy, Gothenburg University. During his PhD at the Department of Endocrine Physiology, he developed and studied transgenic mouse models for studies of early prostate development and mechanisms of hyperplasia. He publishes regularly in peer-reviewed journals and is the author of two text book chapters. Dr Kindblom is a regular reviewer for international journals, among others IJROBP. His clinical practice and research interest is now focused mainly on prostate cancer, specifically optimization of radiotherapy (external and high-dose rate brachytherapy). He has been co-investigator of several phase I-III clinical trials. Dr Kindblom is secretary of the Swedish Society for Urooncology (SFUO). He is also an appointed medical expert serving under the National Board of Health and Welfare in providing national guidelines for prostate cancer care and treatment.

See COI

Matej Knezevic

Matej Knezevic

General Hospital Dr.Josip Bencevic, Urology

Slavonski Brod, Croatia

Disease area: Lower Urinary Tract Dysfunction

Biography:
Matej Knezevic is an urology specialist working in Clinical Hospital Center 'Sestre milosrdnice' in Zagreb, Coratia. He is sub-specialized in the field of urolithiasis. Dr. Knezevic's scientific interest is the exploration of new technologies and their application in surgery. Among other projects, he is coordinating the team for research of three-dimensional printing technologies in urology.

See COI

Pavlo Kolesnyk

Pavlo Kolesnyk

Uzhgorod National University, Family Medicine

Uzhgorod, Ukraine

Disease area: COVID-19

Biography:
Pavlo Kolesnyk is Head of the Department of Family Medicine and Outpatient Care at the Uzhgorod National University, Ukraine and Director of Family Medicine and Outpatient Care Training Centre. He obtained his PH.D M.D. degree in Internal medicine in 2002 and has since specialised as general practitioner and gastroenterologist. Between 2005 and 2020 he was associate professor of the Family Medicine Department of Postgraduate Faculty Uzhgorod National University. Since 2020 he organized and chaired the new department: the Department of Family Medicine and Outpatient Care of Medical Faculty #2. He is an active Council Member of EURACT - WONCA Europe and of EGPRN WONCA Europe. He founded and leads the Charitable foundation “Family” and developed “The ABC of family medicine research” transnational training course. Dr. Kolesnyk is involved in training of post-graduate family doctors and residents, and is currently trainer of mobile teams for COVID-19 vaccination in Ukraine. His research spans from screening and prevention in rural family medicine among Ukrainian population to development of family medicine in post-Soviet countries, as well as risk management for family medicine in Ukraine. His clinical research covers screening and prevention of main non-infectious diseases and implementation of evidence based screening in his country. These interests are reflected in more than 200 publications in national and international journals and books.

See COI

Badrinath Konety

Badrinath Konety

Rush University Medical Center, Urology

Chicago, USA

Disease area: Bladder cancer

Biography:
To be added

See COI

Teele Kuusk

Teele Kuusk

Urology

London, United Kingdom

Disease area: Renal Cell Carcinoma

Biography:
Dr Teele Kuusk graduated from the Medical Faculty of Tartu University, Estonia in 2009. During her medical studies she was a sub-investigator at the Clinical Research Centre, getting her first experience in clinical vaccine and other medical studies. In 2015 she completed her Urology Residency at Tartu University. During her Urology training, she was working mainly in Oulu University Hospital in Finland and in Tartu University Hospital in Estonia but also had Paediatric Urology training in Bezmialem Hospital in Istanbul, Turkey, supervised by Associate Professor Mesrur Selcuk Silay (EAU Crystal Matula Award 2018, Chair of YAU). From 2009-2015 she represented Estonian Urology residents in the European Society of Residents in Urology (ESRU), organised academic training for Estonian Urology residents and also published her first manuscript on renal tumours. From 2007, she has been actively attending local and international meetings and congresses. After her residency, she worked as a Consultant Urologist in Kanta-Häme Central Hospital in Finland. In 2016-2017 she received a prestigious clinical research fellowship by the European Urological Scholarship Programme (EUSP) at the centre of excellence Antoni van Leeuwenhoek Netherlands Cancer Institute in Amsterdam, the Netherlands, where she was supervised by renal cancer leading expert Dr Axel Bex. He is a pioneer in using sentinel lymph node technique in renal tumours for the purpose of studying lymphatic drainage, which became Dr Kuusks topic for her thesis. They have won best poster prize in 2017 for their abstract “Topographic distribution of sentinel lymph nodes in patients with renal tumours” presented at the EAU Congress 2017 held in London. They have published 6 articles on the topic in peer-reviewed Urology journals and have published 12 other articles together and with co-authors. Dr Kuusk is a co-author in the EAU learning module thromboprophylaxis section and a book chapter about sentinel lymph node biopsy in renal cancer. From 2018 she is associate member of the EAU renal cell carcinoma guidelines panel. During her career she has given 12 lectures at local meetings, 4 international congresses as an abstract presenter or a session moderator and 2 times been invited speaker at international renal cancer congresses. In January 2020 she finished her one-year fellowship at the Royal Free Hospital Renal Cancer Unit in London, UK, where she was trained in robotic, laparoscopic and open surgery in renal cancer.

See COI

Annemarie Leliveld

Annemarie Leliveld

University Medical Center Groningen, Urology

Groningen, Netherlands

Disease area: Bladder cancer,Renal Cell Carcinoma

Biography:
Annemarie Leliveld is urologist and staff member at the Department of Urology of the University Medical Center Groningen (UMCG), Groningen, the Netherlands since 2005. In addition, she is Consultant Onco-Urology at the Comprehensive Cancer Center Northern Netherlands. She finished her PhD on urothelial cell carcinoma of the bladder and the upper urinary tract in 2014. Currently, she is also preparing her PhD project on the clinical aspects of diagnosis and treatment of urothelial cell carcinoma. Annemarie Leliveld received her Medical Degree from the University of Groningen, the Netherlands in 1996, and continued her resident training in surgery and urology at the Martini Hospital and Academic Hospital of Groningen, the Netherlands. She became board-certified urologist in 2005 and she obtained the Fellow of the European Board of Urology (FEBU) certificate in 2006. She is specialized in oncology, laparoscopy and endometriosis. She is member of the Dutch Association of Urology and the European Association of Urology, and of several committees at the UMCG, including the committee on endometriosis, laparoscopic surgery, palliative care and rectal carcinoma. She is also member of the National committee on oncological urology and hereditary urological tumours. She is (co-)author of several publications in peer-reviewed journals.

See COI

Börje Ljungberg

Börje Ljungberg

Umeå University, Urology

Umeå, Sweden

Disease area: Renal Cell Carcinoma

Biography:
Börje Ljungberg is a urologist and professor of Urology at the Department of Surgical and perioperative sciences, Urology & Andrology of Umeå University Hospital in Umea, Sweden. He obtained his medical degree from the Medical School of Uppsala and Umeå in 1975, and specialised in Urology and General Surgery in 1983. He defended his PhD thesis on renal cell carcinoma tumour heterogeneity and prognosis in 1986. He is chairman of the Renal Cell Carcinoma EAU Guidelines group since 2005, chairman of the National Swedish Kidney Cancer Registry since 2003, and member of the Nordic Renal Cell Carcinoma Study Group since 2016. He was board member of the Nordic Urologic Association between 2000-2015. Dr. Ljungberg’s research interests are focussed on molecular genetics and angiogenesis in urological malignancies. More specifically, cell cycle regulation, proliferation, prognostic variables and clinical research in renal cell carcinoma. He has tutored several PhD students in these fields of research. He has (co-)authored more than 300 peer-reviewed publications.

See COI

User avatar

Yohann Loriot

Institut Gustave Roussy, Medical Oncology

Villejuif, France

Disease area: Bladder cancer

Biography:
Yohann Loriot is a medical oncologist, physician-scientist at the Gustave Roussy Institute, Cancer Campus of the Université Paris-Saclay in the Villejuif commune of Paris, France. Dr Loriot’s main research interest is the study of the mechanisms mediating progression to lethal disease in cancers of the bladder and prostate with a focus on the development of novel strategies and therapies targeting these conditions at the molecular level. As a member of the steering committees of several international clinical trials, Dr Loriot has published extensively in his specialised field, and has been instrumental in the development of high-impact publications supporting the approval of therapeutic agents including enzalutamide, abiraterone, and atezolizumab. He also co-led the study that led to the approval of the fibroblast growth factor receptor inhibitor erdafitinib. He is currently engaged in the development of ancillary studies to help better understand the mechanisms of action of (and resistance to) targeted therapies and checkpoint inhibitors.

See COI

Angus MacCormick

Angus MacCormick

Taunton & Somerset NHS Foundation Trust, Urology Nurse Specialist

Taunton, United Kingdom

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr. MacCormick has been directly involved in the management of patients with prostate disease for the past 20 years. This includes the assessment, investigation and treatment of patients with lower urinary tract symptoms attributed to bladder outflow obstruction as a result of benign prostatic enlargement. He is also actively involved in the management of both male and female patients with symptoms suggestive of bladder over activity and/or nocturia, including nocturnal frequency, nocturnal polyuria and global poyuria. Prostate Cancer is foremost in the minds of men. This condition is a particular interest of Dr. MacCormick. He is actively involved in the initial assessment, diagnostic investigation and treatment of men who have been diagnosed with prostate cancer. This includes undertaking MRI cognitive Trans Rectal Ultrasound Guided Prostate Biopsies, systematic and targeted and also Trans-perineal prostate Biopsies. He also manages their lower urinary tract symptoms and sexual dysfunction post treatment.

See COI

Stefan Machtens

Stefan Machtens

Marien-Krankenhaus, Urology

Bergisch Gladbach, Germany

Disease area: Prostate cancer

Biography:
Dr. Stefan Machtens is head of the department of urology and pediatric urology at Marienkrankenhaus Bergisch Gladbach, an academic teaching hospital of Cologne University. After his university education in Pecs (Hungary), Bochum and Cologne he graduated in medicine in 1994. After short-term stays in St.George Hosspital in Sydney/Australia and St.Joseph Hospital in Atlanta/USA he finished his medical education at the department of surgery at Knappschafts-Krankenhaus in Dortmund Brackel. Dr.Machtens received his urologist specialist training at Hannover Medical School under Prof. Udo Jonas. He passed his board exam in 1999. Since 2002 he worked as senior staff member at Hannover Medical School. In between 2005 to 2006 he became vice chair at the University Department at Hannover Medical School. In 2003 he received his degree as „Medical Hospital Manager“ after studies at the Fachhochschule Hannover. In 2005 he specialized in „Specialized urologic Surgery“. In 2006 he qualified with the additional qualification „Andrology“ and in 2009 in „Medical Tumor Therapy“. He is member of several national and international urological societies. Since 2007 he is member of the German S3-Guideline Panel for prostate cancer. Since 2008 he is member of the EAU/ESTRO Teaching Staff in „Prostate Brachytherapy“. He has been the Managing Editor of The World Journal of Urology in between 1999-2005. Dr. Machtens has been main investigator in multiple phase I-III uro-oncological trials. Dr. Machtens has presented more than 350 invited lectures. He has published more than 90 peer-reviewed articles as author and co-author. He has published 7 books. Dr. Machtens received six national and international scientific awards on the field of uro-oncology and urologic physiology.

See COI

Bernard Malavaud

Bernard Malavaud

CHU de Toulouse, Hôpital de Rangueil, Urology

Toulouse, France

Disease area: Bladder cancer

Biography:
Bernard Malavaud is Head of Urology and Chief Medical Officer at Toulouse Cancer Institute in Toulouse, France and co-director of the Sphingolipids and Cancer Research Lab at the Institute of Pharmacology and Structural Biology. After his military service as a District Medical Officer in Malawi (East Central Africa) and four years of General Surgery and Urology residency, he obtained his medical degree in 1989. He defended his PhD on tumour angiogenesis in 1997 at the French National Centre for Scientific Research in Paris, France. He was a visiting scientist for one year at the Department of Biomedical engineering of Johns Hopkins University, Baltimore, USA before returning to France for a position as professor of Urology at the University Hospital of Toulouse. Dr. Malavaud was awarded the European Association of Urology 2003 Crystal Matula Award for excellence and dedication to Academic Urology, the Best Scientific Communication EAU 2016 and is a laureate of the French Ministry of Science and Research iLab 2018 (SmartCatch). He is a fellow of the European Board of Urology, board member of the European Association of Urology (EAU) and Association of Academic European Urologists, as well as member of the European School of Urology, the European Society of Uro-Technology and the French Association of Urology (AFU). He has (co-)authored several impactful, peer-reviewed publications.

See COI

Xavier Maldonado

Xavier Maldonado

University Hospital Vall d'Hebron, Radiation Oncology

Barcelona, Spain

Disease area: Prostate cancer

Biography:
Dr Maldonado works as Radiation Oncologist at the Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, He is a member of several national and international associations as well as board member of the G.I.C.O.R. (Spanish Group for Investigation in Radiation Oncology) He is a fellow of the Spanish School in Radiation Oncology and he has chaired several times the prostate cancer courses and genitourinary oncologic meetings. He is also a reviewer of the main Radiation Oncology journals. He is author and co-author of more than 50 papers published in peer reviewed, indexed Journals. His main clinical interest is urological oncology, where he conducted several clinical trials. He is actually focused in the high risk prostate cancer tumors and in the IGRT (Image Guided Radiation Therapy) quality programs. He is the responsible of the Urological tumors in the Radiation Oncology department.

See COI

Christos Markopoulos

Christos Markopoulos

National and Kapodistrian University of Athens, Surgical Oncology

Athens, Greece

Disease area: Breast cancer

Biography:
Professor Markopoulos qualified from Athens University Medical School, Greece in 1979 and he specialized in General Surgery (1985). He received his PhD from Athens University in 1985 and holds an MPhil degree in Oncology – Breast Cancer from St. George’s Medical School, University of London, UK (1988). He specialized in breast cancer management working as Senior Registrar in surgery at the Breast Unit of St. George’s Hospital and Medical School and at The Royal Marsden Hospital in London, UK (1985-1988). He has also worked as research fellow at the Ludwig Institute for Cancer Research at Sutton, Surrey, UK (1986-1987). Professor Markopoulos is the current President of the UEMS – Division of Breast Surgery and head of the examination board of the EBSQ in Breast Surgery exams (2016-2020). He has been an elected member of the European Society of Breast Cancer Specialists (EUSOMA) Executive Committee (2010-2016) and he is a member of several medical associations and societies including the UK Association of Breast Surgery at The Royal College of Surgeons (ABS), American College of Breast Surgeons (ACBS) and the European Society of Surgical Oncology (ESSO). He is the founder of the Hellenic Society of Breast Surgeons (HSBS 2000), which he also served as President from 2000 to 2016, when he resigned to focus on UEMS – Division of Breast Surgery, and he was the head of the education, training and clinical trials section of the society. He is also the head professor of the elective course on “Breast Disease and Cancer” for the students of the final year in the Medical School of the National & Kapodistrian University of Athens in Greece. Professor Markopoulos is national coordinator and principal investigator in a number of international and national research projects and clinical trials and has published over 300 scientific papers in peer-reviewed international and Greek medical journals with more than 7,000 citations by other authors and a current h-index of 39. He has also authored (4) and edited (17) several books on breast disease and cancer, including the “European textbook of Breast Cancer management for Surgeons” (Springer 2018), official book of the EBSQ exams in Breast Surgery. He is President of the scientific committee in two Greek Breast Cancer advocacy groups and Europa Donna Hellas. He has organized a large number of national and international postgraduate courses and meetings on breast cancer over the last 30 years, including the 2-day October meeting on the “Advances in Breast Cancer Management” he organizes annually since 1996. He has lectured extensively as an invited speaker at national and international congresses. He is the recipient of a number of scientific awards during congresses and honorary awards for his work with breast cancer patients.

See COI

Christophe Massard

Christophe Massard

Gustave Roussy Institute, Medical Oncology

Villejuif, France

Disease area: Prostate cancer

Biography:
Christophe Massard (MD, PhD), Medical Oncologist, is Chair of the Drug Development Department (DITEP) at Gustave Roussy, Villejuif, France. He is Consultant Medical Oncologist and full time cancer specialist at Gustave Roussy, half time at the Drug Development department (DDD) and joined the faculty in 2006. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a special interest in Genito urinary cancer and Central Nervous System tumour. Dr Massard received his medical degree from PARIS XI University in 2006, and he got a MSc and PhD from PARIS XI University in 2013. He completed his residency training in Paris Hospital, followed by his fellowship in Medical Oncology at Gustave Roussy. He is board certified in Medical Oncology. He did a post-doctoral fellowship in Prof DeBono’s lab at the Royal Marsden Hospital of London and Institute of Cancer Research (London). Dr Massard is member of ESMO, ASCO, AACR. Over the last 5 years, he was the principal investigators of 15 phase I trials, 1 phase II trial (prostate cancer), and sub investigator of more than 80 clinical trials (phase 1 trials and GU cancers). He is also involved in translational research aspects related to Medical Oncology Precision Medicine(MOSCATO, MATCH R and PETRUS program). Dr Massard has contributed to over 180 peer-reviewed publications, including publications in European Urology, Annals of Oncology and Journal of Clinical Oncology. He is also a member of the editorial boards of Bulletin du Cancer, Investigational New Drugs and European Journal of Cancer. Research axes: early clinical trials, precision medicine, GU cancers (prostate cancer, bladder cancer and testis), glioma, and circulating biomarkers.

See COI

Icro Meattini

Icro Meattini

Azienda Ospedaliero-Universitaria Careggi, Clinical & Radiation Oncology

Florence, Italy

Disease area: Breast cancer

Biography:
Icro Meattini is Associate Professor at the Department of Clinical and Experimental Biomedical Sciences of the University of Florence (Florence, Italy), working as Clinical/Radiation Oncologist since 2011 at the Radiation Oncology Unit of the Oncology Department at the Florence University Hospital. He is responsible for the Outpatient Clinics Unit, Clinical Trials Unit, and leader of the Clinical/Radiation Oncology Group of the Breast Cancer Multidisciplinary Team. He is an active member of the European Society for Radiation Oncology (ESTRO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Society of Medical Oncology (ESMO), the Italian Association of Medical Oncology (AIOM), and the Italian Association for Radiotherapy and Clinical Oncology (AIRO). He is actively involved in the ESTRO and EORTC network, past co-Chair of the Breast Working Party (BWP) of the EORTC Radiation Oncology Group (2016-2019) and current member of the EORTC Radiation Oncology Scientific Council (ROSC), current Chair of the BWP of the AIRO, and current Chair of the Clinical Oncology Breast Cancer Group (COBCG) cooperative network. His main fields of interest are focused on breast cancer, systemic therapy integration, multimodal therapies, health-related quality of life, partial breast irradiation, clinical trials development. He is an author of over 150 peer-reviewed international manuscripts. Father of a wonderful young princess, outside of work he loves reading, traveling, and discovering cultures.

See COI

Axel Merseburger

Axel Merseburger

University Hospital Schleswig-Holstein, Urology

Lübeck, Germany

Disease area: Prostate cancer,Bladder cancer,Renal Cell Carcinoma

Biography:
Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck, Germany. After graduating from Hannover Medical School in 2002, he carried out a residency in surgery and urology at the Eberhard Karls University, in Tübingen, followed by a research fellowship at the Miller School of Medicine, Miami, USA (2006). He became Associate Professor in 2009 and full Professor in 2012 at Hannover Medical School. Professor Merseburger is a member of various uro-oncology organisations and serves as an advisor for the European Association of Urology (EAU) Guideline Group for Renal Cancer and was the Chairman of the EAU Guideline Group for Lasers and Technologies. He acts as reviewer and editorial board member for several urology and oncology indexed journals and is associate editor of the World Journal of Urology and editor of the Advanced Prostate Cancer Resource Centre. Professor Merseburger’s research activity encompasses both molecular and clinical aspects of uro-oncology, with specific interest in biomarkers and prognostic factors for prostate cancer, renal cell carcinoma and transitional cell carcinoma. He has authored and co-authored >200 peer-reviewed articles and he is the principal investigator in multiple phase II and III clinical trials in Germany.

See COI

Nele Michels

Nele Michels

University of Antwerp & EURACT, General Practice

Wilrijk, Belgium

Disease area: Lower Urinary Tract Dysfunction,COVID-19

Biography:
Professor Nele Michels M.D, Ph.D. is general practitioner at a group practice in Antwerp, Belgium, and assistant professor at the Faculty of Medicine and Health Sciences, University of Antwerp (Ph.D. thesis ‘Portfolio learning and assessing at the workplace: development, reliability and validity’, 2012). Since 2020 she is president of EURACT. She is educational coordinator and vice-director of the Educational Committee General Practice at the Centre for General Practice, Antwerp, and co-coordinator of the Skills Lab at the Faculty of Medicine. For the Flemish Interuniversity Centre for the Education of General Practitioners she is director of the Steering Group Workplace Learning. She is Board Member of the Educational Council at the Faculty of Medicine and Health Sciences as well as for the Educational Council at the University of Antwerp. She is an active member of the Scientific Committee of the Dutch-Flemish Society of Medical Education. The focus of her research is medical education, workplace learning, competence-based education, burnout and resilience, and capacity building in GP. She has both national and international publications and is promotor and co-promotor of national and international research PhD projects (e.g. VLIR-UOS TEAM project on intercultural competences, Loja - Ecuador). She coordinates an Erasmus Mobility project with the Tbilis Medical Academy, Georgia.

See COI

Ángel Montero Luis

Ángel Montero Luis

University Hospital HM Sanchinarro, Radiation Oncology

Madrid, Spain

Disease area: Breast cancer

Biography:
Professor Ángel Montero Luis is an attending physician at the Radiation Oncology Department of the Clara Campal Integral Oncology Center (CIOCC), University Hospital HM Sanchinarro, Madrid, Spain. He obtained his Radiation Oncology degree in 2000 and his PhD in Medicine and Surgery from the Universidad Autónoma de Madrid in 2004. Ángel Montero Luis is principal investigator and collaborating researcher in several national and international studies. His educational activities include professor in the International Master’s in Clinical Oncology (University of Francisco de Vitoria) and Advanced Technological Applications in Radiation Oncology (University of Murcia), as well as in Higher Technician Training Degree in Radiotherapy and Dosimetry (Center for Biosanitary Professions HM Hospitals). Ángel Montero Luis is coordinator of the Spanish Group of Radiation Oncology in Breast Cancer (GEORM). He is also co-inventor of the IRMAPRON® device, immobilizer for radiotherapy of the breast in the prone position, and co-director of the iOncoR mobile application. He is (co-)author of more than 50 scientific publications and 40 chapters in (inter)national books.

See COI

Hugh Mostafid

Hugh Mostafid

Royal Surrey Country Hospital, Urology

Surrey, United Kingdom

Disease area: Bladder cancer

Biography:
Hugh Mostafid qualified from St Thomas's Hospital London in 1989 and trained at Guy's Hospital and the Institute of Urology in London. He became a Consultant Urologist in 2001 and currently works at the Regional Bladder Cancer Centre at the Royal Surrey County Hospital in Guildford, one of the few centres in the UK performing robotic radical cystectomy. He is also an Honorary Senior Lecturer at the University of Surrey in Guildford where his main research interests are the diagnosis and treatment of bladder cancer. He is a past member of the NICE bladder cancer guidelines group and currently an expert advisor to NICE on bladder cancer. He is also a member of the EAU non-muscle-invasive bladder cancer guideline panel He also is the Chief Investigator for a number of UK bladder cancer trials. He has published over 70 papers and several book chapters on bladder cancer.

See COI

Nicolas Mottet

Nicolas Mottet

University Hospital St. Etienne, Urology

Saint-Etienne, France

Disease area: Prostate cancer

Biography:
Professor Nicolas Mottet is head of the department of Urology at Centre Hospitalier Universitaire in Saint-Etienne, France and Professor of Surgery at the Jean Monnet University, Saint-Etienne, France. Professor Mottet is board certified in surgery, urology and medical oncology in France. He obtained his MD and his PhD from University Montpellier I. Professor Mottet serves as Chairman of the European Association of Urology Working Group on Prostate Cancer Guidelines, as a board member of the Urology Group for the French Anti-Cancer Centre Federation, and as a member of the International Society of Geriatric Oncology Prostate Cancer Guidelines board. He is also a member of the American Urological Association, the American Society of Clinical Oncology, the European Society for Medical Oncology and the French Urological Association, where he served as Coordinator for the Testis and Penile Cancer Subgroup between 2000 and 2008. He is also a member of the New York Academy of Science. Professor Mottet has published over 160 peer reviewed papers, mainly on urologic oncology and prostatic disorders, and has made numerous presentations and lectures. He is an editorial board member of the European Urology Journal and a reviewer of more than a dozen journals, including the New England Journal of Medicine. He is on the scientific advisory board of several pharmaceutical and biotech companies in urology and oncology drug development and clinical trials and has coordinated or participated to more than 40 clinical studies. Professor Mottet has received several peer reviewed grants and is currently coordinating studies on prostate and bladder cancer.

See COI

Sandra Nad

Sandra Nad

University Hospital Centre, Urology

Zagreb, Croatia

Disease area: Lower Urinary Tract Dysfunction

Biography:
To be added

See COI

Matthias Oelke

Matthias Oelke

St. Antonius-Hospital, Urology

Gronau, Germany

Disease area: Lower Urinary Tract Dysfunction

Biography:
Matthias Oelke is assistant medical director and the head of the study & science center of the Department of Urology at the St. Antonius Hospital in Gronau, Germany and associate professor of urology at the Hannover Medical School, Hannover, Germany. He primarily focuses on Functional & Reconstructive Urology as well as on Endourology. Dr. Oelke studied medicine in Hannover, Germany where he also conducted his residency in the Department of Urology from 1996 to 2001. In 2003, he passed the examination of the European Board of Urology (Part I). In 2004, Dr. Oelke completed his German doctoral thesis with summa cum laude and, in the same year, he joined the Department of Urology at the Academic Medical Centre in Amsterdam, where he worked as Section Head of Functional & Reconstructive Urology. In 2005, Dr. Oelke completed the Examination of the European Board of Urology (Part II) and was appointed as Fellow of the European Board of Urology, FEBU. Dr. Oelke returned to the Hannover Medical School in Germany in 2008 where he became Vice-Chairman and Associate Professor in 2010. Dr. Oelke successfully defended his international PhD-thesis in Amsterdam in June 2016. He worked at the University of Maastricht, the Netherlands in the year 2017 and changed to the St. Antonius Hospital in Gronau, Germany in 2018. Dr. Oelke is an active member in many societies including the European Association of Urology (EAU), International Continence Society (ICS), International Consultation on Incontinence-Research Society (ICI-RS), Dutch Society of Urology (NVU), the German Society of Urology (DGU), German League of Urologists (BDU), and the German Society of University Teachers. He was chairman of the ‘EAU Guidelines on Male LUTS’ from 2004 to 2012 and panel member until 2014. Dr. Oelke has been member of the DGU ‘Expert Group on Functional Urology’ since 2009. Additionally, Dr. Oelke has been member of the DGU ‘Expert Group on BPH’ since 2001 and was the chairman of this group from 2015 to 2017. He joined the ‘Standardization Steering Committee’ of the ICS in 2017. He was awarded with 16 national or international prizes and received three research grants. Dr. Oelke is a reviewer of more than 20 medical journals, has authored 90 original scientific articles, 99 review articles and 35 book chapters, and published 4 books.

See COI

Birgitte Offersen

Birgitte Offersen

Aarhus University Hospital, Clinical Oncology

Aarhus, Denmark

Disease area: Breast cancer

Biography:
Birgitte Offersen is Head of the Danish Breast Cancer Group (DBCG) Radiotherapy Committee. Her main focus is radiation therapy of early breast cancer. She is principal investigator of 5 randomised, clinically controlled trials: DBCG HYPO trial, DBCG PBI trial, Skagen Trial 1, DBCG RT Natural trial and DBCG Proton trial. She is a teacher at the European Society for Radiotherapy and Oncology (ESTRO) course for Multidisciplinary management of breast cancer, at the ESTRO online course for target delineation in adjuvant breast radiotherapy, and at the ESTRO course on partial breast irradiation.

See COI

Aurelius Omlin

Aurelius Omlin

Kantonsspital St. Gallen, Medical Oncology

St. Gallen, Switzerland

Disease area: Prostate cancer

Biography:
Dr Omlin is Medical Oncologist at Kantonsspital St. Gallen in Switzerland During his career, Dr Omlin has been involved in early clinical trials (phase I and II), translational research and genitourinary oncology. In recent years, he has been involved in several trials exploring the use of enzalutamide, carboplatin and abiraterone in prostate cancer Dr Omlin received an American Society of Clinical Oncology award in 2013 and is a member of the European Society for Medical Oncology and Swiss Working Group on Clinical Cancer Research

See COI

Piet Ost

Piet Ost

Ghent University Hospital, Radiation Oncology

Ghent, Belgium

Disease area: Prostate cancer

Biography:
Prof. Dr. Piet Ost works as Radiation Oncologist at Ghent University Hospital, Ghent, Belgium. He is a member of several national and international associations and is vice chairmain of the EAU Young Academic Urologists Prostate Cancer Working Party. He is author and co-author of several papers published in peer reviewed, indexed journals. His clinical and research interests are urological oncology with a specific focus on postoperative prostate cancer radiotherapy and metastasis-directed therapy for oligometastatic prostate cancer. More broadly he implemented stereotactic body radiotherapy (SBRT) for oligometastatic solid tumors at his department and developed a research interest in the combination of SBRT with immunomodulatory agents such as anti-CTLA4 and anti-pd1 antibodies.

See COI

Priyanka Patel (Associate)

Priyanka Patel (Associate)

The Royal Marsden NHS Foundation Trust, Clinical Oncology

London, United Kingdom

Disease area: Prostate cancer

Biography:
To be added

Lisa Pickering

Lisa Pickering

Clinical Oncology

London, United Kingdom

Disease area: Renal Cell Carcinoma

Biography:
Dr Lisa Pickering is a Consultant Medical Oncologist who specialises in the treatment of renal, skin and prostate cancers. Dr Pickering gained an honours degree in Physiological Sciences from the University of Oxford in 1992 and her medical degree in 1995 from the University of London. She trained in Medical Oncology at Guy’s and St Thomas’, St George’s and Royal Marsden Hospitals. She was awarded a PhD from the University of London in 2007. She was appointed to St George’s and the Royal Marsden in 2008 as a Consultant Medical Oncologist. At St George’s she was Clinical Lead for Oncology and Palliative Medicine from 2011 and Divisional Chair of Medicine from 2015. She has published more than 30 peer-reviewed papers and has been involved in more than 50 clinical trials. Her major interest is in improving the outcome of renal, skin and prostate cancers. In particular, she is interested in the development of new treatments, determining how to individualise patient treatment and making those advances available to patients.

See COI

Bradley Pieters

Bradley Pieters

Academic Medical Center, Radiation Oncology

Amsterdam, Netherlands

Disease area: Prostate cancer

Biography:
Bradley R. Pieters, MD, PhD, is Head of the Brachytherapy department at the Amsterdam University Medical Centers (location AMC), The Netherlands. Dr. Pieters is the Course Director of the European Society for Therapeutic Radiology and Oncology (ESTRO) School for the Comprehensive and Practical Brachytherapy course and chair of the GEC-ESTRO Committee. Dr. Pieters was trained in Radiation Oncology at the Radboud University Hospital in Nijmegen, The Netherlands, and received his medical degree in 1990. He completed his residency in radiotherapy at Academic Hospital Nijmegen, The Netherlands. Dr. Pieters then completed a brachytherapy fellowship at the Daniel den Hoed clinic in Rotterdam and L'Institut Gustav-Roussy in Villejuif, France. His brachytherapy training was completed at the Academic Medical Center in Amsterdam. Dr. Pieters received his MSc in epidemiology in 2006 and his PhD in 2010 after defending his thesis “Pulsed-dose rate brachytherapy in prostate cancer.” Dr. Pieters’ main field of interest is general brachytherapy with an emphasis on urologic brachytherapy, gynecologic brachytherapy, and pediatric brachytherapy. Dr. Pieters is currently the Principal Investigator of the PROBACH trial (Randomized Phase 3 Study on the Assessment of Late Toxicity by Comparing IMRT High Dose External Beam Radiotherapy Only With External Beam Radiotherapy Combined With HDR or PDR Brachytherapy in Patients With Intermediate/High Risk Prostate Cancer) and POWER trial (Randomized Trial to Evaluate Erectile Dysfunction after Whole or Partial Gland Prostate Brachytherapy. He is also working on the following research projects: multimodality dose summation assessment and evaluation for cervical cancer; quantification of treatment-induced growth disruption using 3D photography in children with (orbital) rhabdomyosarcoma; ICT-based innovations in the battle against cancer – next-generation patient-tailored brachytherapy cancer treatment planning. Dr. Pieters is co-editor of the Journal of Contemporary Brachytherapy and serves as a referee for the following journals: Radiotherapy and Oncology; International Journal of Radiation Oncology Biology and Physics; Brachytherapy; the Journal of Contemporary Brachytherapy; Physics and Imaging in Radiation Oncology.

See COI

Katja Pinker-Domenig

Katja Pinker-Domenig

Medical University of Vienna, Biomedical Imaging and Image-guided Therapy

Vienna, Austria

Disease area: Breast cancer

Biography:
Dr. Pinker-Domenig is Professor of Radiology and Attending at the Department of Radiology, Breast Service at the Memorial Sloan-Kettering Cancer Center, New York, USA. She is the Head of Translational Imaging Research and Head of Breast MRI (magnetic resonance imaging). She is an expert in translational and clinical breast and oncologic gender imaging. Her research interests focus on molecular breast imaging with advanced high-field/ultra-high-field MRI using multiple advanced MRI parameters and hybrid techniques, such as positron emission tomography (PET)/MRI with specific tracers and the application of artificial intelligence in oncologic imaging to develop imaging biomarkers for precision medicine. Dr. Pinker-Domenig’s research won her 15 competitive grants and 16 research awards. She serves as an Executive Board Member of the European Society of Breast Imaging (EUSOBI), Editor-in-Chief for “British Journal of Radiology Open“, Deputy Editor of the “Journal of Magnetic Resonance Imaging” and is editorial board member in several journals such as of “Insights into Imaging”, “European Radiology”, Radiology: Imaging Cancer and “Breast Care”. She has published more than 180 peer-reviewed papers in breast and oncologic imaging (h-factor 41, https://scholar.google.com/citations?user=h0S3S_MAAAAJ&hl=en).

See COI

Guillaume Ploussard

Guillaume Ploussard

Saint Jean Languedoc Hospital and Institut Universitaire du Cancer, Urology

Toulouse, France

Disease area: Prostate cancer

Biography:
Guillaume Ploussard (MD, PhD) is working as uro-oncologist in Toulouse, France, at Saint-Jean Languedoc Hospital and Institut Universitaire du Cancer - Oncopole. After Medical School at the University of Paris, he completed during his training a robotics fellowship at the Department of Urology, McGill University in Canada. His main interests include basic (biomarkers in prostate cancer) and clinical (focal therapy, minimally invasive techniques, fusion biopsies) research that has been funded by research grants in uro-oncology. Guillaume Ploussard is managing editor of World Journal of Urology, section editor of European Urology Today, member of the sub-committee at the EAU section of Oncological Urology, chairman of the EAU working group on prostate cancer and member of the French Cancerology Committe (CC-AFU). He has published more than 160 articles in peer-reviewed journals and received multiple national and international awards for his work.

See COI

Philip Poortmans

Philip Poortmans

Iridium Kankernetwerk, Radiation Oncology

Antwerp, Belgium

Disease area: Breast cancer

Biography:
Philip Poortmans is a radiation oncologist in Antwerp, Belgium, specialised in breast cancer and intraoperative radiation therapy (IORT), including FLASH research. In addition, he is an advisor on FLASH IORT for Sordina IORT Technologies, Aprilia, Italy. In his previous functions, he was head of the radiation oncology departments of Institut Curie, Paris, France (2017-2019) and of the Radboud university medical centre in Nijmegen, the Netherlands (2014-2017). Since 2017, he is Marie Curie Professor of the Paris Science and Lettres University and Institut Curie in Paris, France. Philip Poortmans obtained his medical degree at the University of Antwerp, Belgium in 1986 and completed his radiation oncology training at the Middelheim and Vincentius Hospitals in Antwerp, Belgium. In 2005, he obtained his PhD degree on quality assurance in breast cancer clinical trials at the University of Maastricht, the Netherlands. He is passionate about teaching, as evident from his role as course director and liaison person for different multidisciplinary courses of the European Society for Radiotherapy and Oncology (ESTRO). Currently, he is also member of the faculty for educational activities of the European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO) and the European School of Oncology (ESO). Philip Poortmans is an editorial committee member for several international journals and breast cancer guidelines (European Society of Breast Cancer Specialists (EUSOMA), ESTRO, ESMO, St Gallen) and for cancer and pregnancy. He was previously elected president of ESTRO and the European Cancer Organisation (ECCO), among others. He has (co-)authored more than 250 peer-reviewed publications and several book chapters.

See COI

Camillo Porta

Camillo Porta

University of Bari ‘A. Moro’, Medical Oncology

Bari, Italy

Disease area: Renal Cell Carcinoma

Biography:
Camillo Porta is Chair of Oncology at the Department of Biomedical Sciences and Human Oncology at the University of Bari ‘A. Moro’ in Bari, Italy. He obtained his Medical Degree in 1989 from the University of Pavia, where he specialized in Medical Oncology in 1993. Before his current position, he was Associate Professor of Medical Oncology and Director of the Post-Graduate School of Specialization in Medical Oncology at the University of Pavia and Chief of the Division of Translational Oncology at the IRCCS Istituti Clinici Scientifici Maugeri in Pavia. Dr. Porta’s main clinical and research interests are kidney cancer and the development of novel agents for this disease, for which he is involved in several clinical trials. He has been awarded a prize from Schering-Plough for his experimental work on free radicals, free radical scavengers, and cancer, and the Gaetano Fichera Memorial Prize in Medical Oncology from the University of Pavia. Dr. Porta is a member of the European Society of Medical Oncology (ESMO) Scientific Committee, among various other oncology societies. He has (co-)authored more than 300 publications in peer-reviewed journals and is the Editor-in-Chief of Oncology Reviews.

See COI

Javier Puente

Javier Puente

Hospital Universitario Clinicos San Carlos, Medical Oncology

Madrid, Spain

Disease area: Prostate cancer

Biography:
Javier Puente was born in Madrid (Spain) in 1977. He received his medical degree in 2001 at the Complutense University of Madrid (Spain) followed by his fellowship in 2002. He received his Advanced Study Accreditation (DEA) degree at Complutense University of Madrid in 2004 while completing the medical oncology program at Hospital Clinico San Carlos, Madrid, under the direction of Professor Eduardo Díaz-Rubio from 2002-2006. Dr. Puente earns his Doctorate in Medicine (PhD) with a mention of “Cum Laude” in 2007 followed by a special prize of doctorate in 2009 at Complutense University of Madrid (Spain). Dr. Puente served as resident in the Medical Oncology Department at Hospital Clinico San Carlos from 2002-2006 at which point he became one of the clinical lead and researcher in the Thoracic, Urinary and Melanoma Cancer Unit. Today, he is the Director of the Institute of Oncology at that hospital. From 2006-2010 he was also Honorific Professor at the Complutense University of Madrid (Spain) where he was named Associate Professor of Medicine in 2011. In 2009, Dr. Puente was named National Medical Advisor at Asociación Española contra el Cáncer (AECC) and Staff Researcher of Clinical Trials Spanish Plattform (CAIBER) at Hospital Clinico San Carlos. He served as a member of the Scientific Board of the Spanish Medical Oncology Society (SEOM) from 2013-2015 and joined the Local Ethics Committee at Hospital Clinico San Carlos in 2015 where he continues to serve as a member. Also, in that year, he became a clinical associated with the Centro Nacional de Investigaciones Oncológicas (CNIO). In addition to SEOM and CNIO, Dr. Puente is also a member of the Spanish Lung Cancer Group (GECP), since 2009, the Spanish Oncology Genitourinary Group (SOGUG), since 2009, the Spanish Group of Orphan and Rare Tumors (GETHI) ,since 2009, and he is a member of the American Cancer Society (ASCO) and European Society of Clinical Oncology (ESMO). Dr Puente has been involved with multiple independent research projects, multiple publications and presented at countless national and international conferences.

See COI

Elie Rassy (Associate)

Elie Rassy (Associate)

Gustave Roussy Institute, Medical Oncology

Villejuif, France

Disease area: Bladder cancer

Biography:
Elie Rassy MD, MSc is currently finishing an oncology fellowship at the Gustave Roussy Institute, Villejuif, France and is intending to start another fellowship at the Royal Marsden NHS Foundation Trust in London, UK. He received his medical degree in 2014 and a master’s degree in Biological and Medical Sciences in 2016 both from Saint Joseph University in Beirut, Lebanon, and trained in Internal Medicine and Hematology/Oncology at the Hôtel-Dieu de France University Hospital, Beirut, Lebanon. Currently, he is completing a master’s degree in Public Health (Methodology and statistics in Biomedical Research) at the Paris-Sud University, Paris, France. Dr Rassy has had wide collaboration with centers across Europe and USA, and has co-authored more than 110 peer-reviewed articles in international journals. His main research interests in oncology are cancers of unknown primary, urogenital and gynecological tumors and he has been invited speaker in several international congresses on subjects related to these malignancies.

See COI

Jon Rees

Jon Rees

Backwell & Nailsea Medical Group, General Practice

North Somerset, United Kingdom

Disease area: Lower Urinary Tract Dysfunction

Biography:
Jon Rees trained in Urology in Taunton and became a Member of the Royal College of Surgeons in 1999. He then spent 3 years completing research into the impact of prostate cancer on the quality of life of men and their partners, and was awarded his MD thesis in 2003. In 2004 he switched to General Practice and is now a partner at Tyntesfield Medical Group in North Somerset. He continues to work in Urology, providing a primary care diagnostic urology service to 3 CCG's, including a community based LUTS, Haematuria and raised PSA one-stop service. He is a founding director of Shire Health, providing Urology Advice & Guidance services to 2 CCG’s and running a Community Urology service in Gloucestershire. He was a member of the Guideline Development Group for the NICE 'Lower Urinary Tract Symptoms in men' Clinical Guideline, published in 2010 and an Expert Advisor to the NICE Quality Standard for Prostate Cancer in 2015. He is deputy editor of ‘Trends in Urology and Men’s Health’ (www.trendsinurology.com) and involved extensively in educating his fellow GP’s about Urology, particularly through the Prostate Cancer UK Masterclasses. He is currently chair of the educational advisory group for Prostate Cancer UK, previously chair of the ‘Prostatitis Expert Reference Group’ at Prostate Cancer UK and a member of the Clinical Advisory Board for ‘Tackle Prostate Cancer (formerly known as the Prostate Cancer Support Federation). In 2014, he founded (and now chairs) the Primary Care Urology Society – for GP’s with an interest in Urology or who wish to develop skills in this area. (www.primarycareurologysociety.org) In June 2015 he became a trustee of the charity ‘Action on Bladder Cancer UK’. In his ‘spare time’, he is an active trustee of the Health Improvement Project Zanzibar (www.hipz.org.uk) – a small UK based charity which runs 2 district hospitals on the island of Zanzibar, providing essential healthcare for over 250,000 people.

See COI

Subodh K. Regmi

Subodh K. Regmi

University of Minnesota, Urology

Minneapolis, USA

Disease area: Bladder cancer

Biography:
Subodh K. Regmi is an Urologic Oncologist currently working as Assistant Professor at the Department of Urology at University of Minnesota. He has completed his medical education at the Manipal College of Medical Sciences in Nepal, his general surgery and urology training at the All India Institute of Medical Sciences in New Delhi, India, and his urologic oncology fellowship at University of Minnesota in the United States. By working in Nepal, India and the United States, he has gained a diverse urological experience. He is particularly intrigued with non-muscle invasive and muscle invasive bladder cancer, and the multifaceted management of bladder cancer patients. He (co-)authored more than 30 publications.

See COI

Mesut Remzi

Mesut Remzi

Regional Hospital of Weinviertel-Korneuburg, Urology

Korneuburg, Austria

Disease area: Prostate cancer

Biography:
Mesut Remzi did his residency and his “Habilitation” at the Medical University of Vienna. Recently he became vice chairman at the Landesklinikum Korneuburg. His clinical activity is uro-oncology, mainly kidney tumors, prostate cancer and upper urinary tract urothelial carcinoma. He is specialised in laparoscopic surgery. Right now he is the primary investigator for an international, multicenter collaborative trial on organ-sparing surgery on upper urinary tract urothelial carcinoma (OSS-UTUC). He is (co)-author of more than one hundred peer-reviewed original articles. He was reviewer of the moth for European Urology and is member as Editor at glace for European Urology, Editor in the World Journal of Urology and reviewer for many urologic journals.

Maria Ribal

Maria Ribal

University Hospital Clinic Barcelona, Urology

Barcelona, Spain

Disease area: Prostate cancer

Biography:
Maria J. Ribal received her medical degree in 1994, followed by her PhD in 2002, both at the University of Barcelona. She attended as Visiting Clinician at Mayo Clinic in Rochester (USA) in 2002. Fellow in Laparoscopic Surgery at the University College London Hospital (UCLH) from June till December 2006. She has been member at the Oncology Unit of the Department of Urology at Fundacio Puigvert (2002-2005). Since February 2005, she is member of the Department of Urology at the University Hospital Clinic of Barcelona. Currently, she is Associated Professor of Surgery at the University of Barcelona. From December 2011 she is the Head of the Uro-Oncology Unit at Hospital Clinic, that comprises a multidisciplinary team: urologists, medical oncologists, radiation oncologists, pathologists, radiologists, nutritionists, nurses and all those involved in the manage and therapy of uro-oncological malignancies. Her main interest is Uro-Oncology and renal transplantation. She is actively involved in translational research in the field of urological malignancies and actively involved in clinical research at the Uro-Oncology Unit She is the author of over hundred international and national publications, 10 book chapters, and > 300 invited lectures at conferences and courses. She is an active member of European Association of Urology (EAU): Member of the Muscle Invasive and Metastatic Bladder Cancer Guidelines Group of the EAU since 2006 and vice-chair since 2018, Member of the EAU section of Uro-Technology (ESUT) since 2010. Board member of the European Urological Scholarship Programme of the EAU (EUSP) since April 2012 and Board Member of the EAU Guidelines Office since January 2016. In 2009, during the EAU Annual Meeting held in Stockholm, she received the Crystal Matula award, a prestigious prize granted to a young promising European urological academician.

See COI

Arabelle Rieder

Arabelle Rieder

Geneva University Medical School, Family Medicine

Geneva, Switzerland

Disease area: COVID-19

Biography:
Dr Arabelle Rieder is a general practitioner in a group practice in Geneva, Switzerland, with training in General Internal Medicine and specialisation in addiction medicine and motivational interviewing. She supervises undergraduate students in clinical practice and is a part-time lecturer in Family Practice at Geneva University Medical School. She is in charge of Faculty development in Family Medicine and participates in research on medical education. She is the Swiss council member of the European Academy of Teachers in General Practice/Family Medicine (EURACT).

See COI

Julia Ring (Associate)

Julia Ring (Associate)

University Hospital Schleswig-Holstein, Urology

Lübeck, Germany

Disease area: Renal Cell Carcinoma

Biography:
Julia Ring obtained her medical degree from the University of Lübeck, Germany in 2015. She is currently a resident of urology at the University Hospital Schleswig-Holstein in Lübeck, Germany and will become a specialist in urology in the summer of 2020. In 2017, she obtained her PhD in gynaecology, entitled: “Early-onset breast cancer: effect of diagnosis and therapy on sexuality, endocrine system and fertility concerns of young mothers in Germany”. Currently, her main clinical and research interests are focussed on kidney and prostate. Julia Ring is a member of the German Association of Urology, the European Association of Urology and the German Society of Residents in Urology. Furthermore, she is participating in a mentoring programme for women of the University Hospital Schleswig-Holstein. She has (co-)authored several peer-reviewed publications.

See COI

Sylvie Rottey

Sylvie Rottey

Ghent University Hospital, Medical Oncology

Ghent, Belgium

Disease area: Renal Cell Carcinoma

Biography:
Sylvie Rottey studied Medicines at the Ghent University in Belgium and is staff member of the department of Medical Oncology (from October 2003). She is head of the department of Medical Oncology at the Ghent University Hospital as well as head of the Drug Research Unit Ghent. She is principle investigator of numerous phase I - III clinical trials since more than 10 years. She is Medical Oncologist and Professor in Pharmacology, certified as Clinical Pharmacologist since 2008 (Dutch Society for Clinical Pharmacology & Biopharmacy). Sylvie Rottey publishes in national and international peer-reviewed journals. She is president ad interim of BSMO, member of ESMO, member of ASCO, board member of VWHHT (https://vwhht.be/), member of EORTC, president of BMUC (https://bmuc.be/), board member of Healixia (https://www.healixia.be/) and member of Eufemed (https://www.eufemed.eu/).

See COI

Isabel T. Rubio

Isabel T. Rubio

Clinica Universidad de Navarra, Surgical Oncology

Madrid, Spain

Disease area: Breast cancer

Biography:
Isabel T. Rubio is the Head of Breast Surgical Oncology at Clinica Universidad de Navarra in Madrid, Spain and Professor of Surgery at the Universidad de Navarra, Spain. She completed her Medical degree at the Faculty of Medicine in Salamanca, Spain, and became a Board-certified General Surgeon. She had additional training for two years as a Breast Surgical Oncology Fellow at The University of Arkansas for Medical Sciences and the Arkansas Cancer Center at Little Rock, USA and for one year at the MD Anderson Cancer Center in Houston, Texas, USA. She completed her PhD in 2000. She is the director of the Breast Surgery Fellowship program at her Institution. Dr. Rubio is active in many societies, founding member and past President of the Spanish Association of Breast Surgeons (AECIMA), EUSOMA President-elect (European Society of Breast Cancer Specialists), Chief Public Affairs of the European Society of Surgical Oncology (ESSO), member of the American Society of Breast Surgeons (ASBrS) and in 2017 member of the Outreach Committee of the Society of Surgical Oncology (SSO). She is breast section editor of the Journal of Surgical Oncology, reviewer for The Breast, and the European Journal of Surgical Oncology. She obtained the European Board of Surgery Qualification in Breast Surgery and, since 2015, is officer at the UEMS Breast Surgery Division and participates as an examiner in the EBSQ Examinations in Breast Surgery. Dr. Rubio is involved as part of the Steering and Executive Committees in several international, multicenter randomized trials. She has received grants to develop her research by the Susan G. Komen Foundation, Spanish Ministry of Health and other institutions. Dr. Rubio has published over 100 national and international peer-reviewed manuscripts and book chapters. She has presented her work in many of the main international meetings in breast cancer. Her interest is in sentinel lymph node biopsy, neoadjuvant treatments, surgical management of BRCA mutation carriers and the role of prognostic markers (genomic profiles, liquid biopsy). Also, her interest is focused on the standardization of breast cancer surgical training and Breast units.

See COI

Roberto Salgado

Roberto Salgado

GZA Antwerp, Pathology

Antwerp, Belgium

Disease area: Breast cancer

Biography:
Dr. Salgado is board certified in Anatomical Pathology since 2006. After his graduation as an Anatomical Pathologist, he worked as a consultant Pathologist for the Breast International Group (BIG). As a member of the Aurora Working Group, he helped develop the Aurora Molecular Screening Program for Metastatic Breast Cancer Patients. Currently, he carries out surgical pathology at the Department of Pathology at the GZA/ZNA Hospitals Antwerp, Belgium. He is a scientific collaborator of the Immuno-Task Force of the Breast International Group and an Honorary Research Associate at the Division of Research at the Peter MacCallum Cancer Centre, Melbourne, Australia. Currently, he chairs an International Consortium of Pathologists, namely the “International Immuno-Oncology Biomarkers Working Group” (www.tilsinbreastcancer.org) which develops guidelines for the assessment of immuno-oncological biomarkers in cancer. He works in close collaboration with the EORTC. Dr. Salgado’s strategic views on Oncology have been published in major international high impact factor journals including Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery and Lancet Oncology. His research has been published in Nature, Nature Medicine, Lancet Oncology and Journal of Clinical Oncology, among others. He has developed a specific expertise in the Molecular Pathology of solid tumours, circulating tumour biomarkers, next generation sequencing technologies, validation of biomarkers, innovative clinical trials incorporating genomics, quality assurance of genomic technologies and development of biomarkers in immunotherapeutic trials, with a focus on Tumour Infiltrating Lymphocytes (TILs).

See COI

Paul Sargos

Paul Sargos

Institut Bergonié, Centre Régional de Lutte Contre le Cancer, Radiation Oncology

Bordeaux, France

Disease area: Prostate cancer,Bladder cancer

Biography:
Paul Sargos is a radiation oncologist with strong interest in onco-urology, an area in which he has published more than 60 peer-reviewed articles. He coordinates the GETUG-AFU 30 and GETUG-AFU 17 prospective clinical trials on postoperative radiotherapy of bladder and prostatic tumors, respectively. As an active member of scientific societies such as the GETUG, the AFU, the SFRO in France, as well as the GFRU and the Young-EAU Working Party on Bladder cancer on a European scale, Paul has collaborated with french and international onco-urologic community.

See COI

Cristina Saura

Cristina Saura

Vall d’Hebron University Hospital, Medical Oncology

Barcelona, Spain

Disease area: Breast cancer

Biography:
Dr. Cristina Saura graduated in Medicine at the University of Barcelona, Spain in 2002 and carried out her training in Medical Oncology at the Vall d’Hebron University Hospital, Barcelona, where she has been working in the Department of Medical Oncology since 2007. Currently, she is the head of the Breast Cancer Unit at the Vall d’Hebron University Hospital and principal investigator of the Breast Cancer & Melanoma Unit at the Vall d’Hebron Institute of Oncology. She presented her research sufficiency project with the title "Programme for early detection of breast cancer in women with high risk: pilot monitoring experience with mammography and breast MRI" in 2007 obtaining outstanding qualification. To pursue her interests in clinical research, she joined the Program in Clinical Effectiveness at the Harvard School of Public Health, Boston, MA, USA in 2007. She obtained her PhD from the Autonomous University of Barcelona in 2017 under the title “Treatment of breast cancer diagnosed during pregnancy” with cum laude qualification. Dr. Saura has participated as principal investigator and co-investigator in several Breast Cancer clinical trials. She is actively involved in developing various international studies involving drugs directed against molecular targets in breast cancer. She is especially dedicated to advancing precision oncology and has become a reference in the development of different PI3K inhibitors and anti-HER2 therapies. She is the author of several publications and communications in national and international congresses. In addition, Dr. Saura is member of Scientific Committee and Board of Directors of the group SOLTI (Academic research group in breast cancer) and member of the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the Spanish Association of Medical Oncology (SEOM) and GEICAM (Spanish Breast Cancer Research Group).

See COI

Manuela Schmidinger

Manuela Schmidinger

Medical University of Vienna, Medical Oncology

Vienna, Austria

Disease area: Renal Cell Carcinoma

Biography:
After graduating as Medical Doctor from the Medical University of Vienna, Austria in 1992, Prof. Manuela Schmidinger specialised at the same institution in Internal Medicine in 2000 and in Medical Oncology and Haematology in 2002. In 2002, she obtained her venia legendi in Internal Medicine and became Professor of Medicine at the Medical University in Vienna. She specialised in Intensive Care Medicine in 2008 at the Medical University in Vienna. Currently, she is senior physician at the Clinical Division of Oncology within the Department of Medicine at the Medical University of Vienna. She is also Programme Director for renal cell carcinoma and is responsible for the generation of clinical study protocols, basic science in the field of kidney cancer and care of patients with renal cell carcinoma. She is author of more than 100 peer-reviewed papers and contributed to several books (under the name of Schmidinger or former Djavanmard).

See COI

Astrid Scholten

Astrid Scholten

The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Radiation Oncology

Amsterdam, Netherlands

Disease area: Breast cancer

Biography:
Astrid Scholten is a radiation oncologist at The Netherlands Cancer Institute, Antoni van Leeuwenhoek, in Amsterdam. She completed her specialist training at The Leiden University Medical Center in 2006 and remained working there as a radiation oncologist until 2013, when she switched to The Netherlands Cancer Institute in Amsterdam. Her fields of expertise are breast cancer and sarcomas. After gaining her PhD degree in 2005, her research focusses on clinical de-escalation studies in breast cancer. Furthermore, she has a lead role in education and training for specialist registrars.

See COI

Carolien Schröder

Carolien Schröder

University Medical Centre Groningen (UMCG), Medical Oncology

Groningen, Netherlands

Disease area: Breast cancer

Biography:
Carolien Schröder is a medical oncologist, with a focus on breast cancer, at the department of Medical Oncology of the University Medical Center Groningen (UMCG), the Netherlands. She conducts large scale multicenter clinical breast cancer trials within the Netherlands and beyond, and has her own preclinical research line regarding the breast cancer microenvironment. She has procured funding for her research efforts from several sources, including the Dutch Cancer Society. Her research as PI is embedded in the Cancer Research Center Groningen, the Netherlands. After her thesis ‘New ways to optimize breast cancer treatment’ (2001), her residency Internal Medicine (2006) and fellowship Medical Oncology (2008), she was appointed as staff member at the department of Medical Oncology of the UMCG, and associate professor at the Rijksuniversiteit Groningen, the Netherlands. As research fellow, she worked in Fox Chase Cancer Center, Philadelphia (lab of Prof. Thomas Hamilton) and at Harvard Medical School, Dana Farber Cancer Center, Boston, USA (with Prof. Eric Winer and Dr. Beth Overmoyer). Schröder’s research focus is to explore novel rational treatment options to enhance therapeutic efficacy and personalized medicine, in interdisciplinary, translational research. This has led to breast cancer research regarding preclinical and clinical intervention strategies directed at the breast cancer microenvironment and metastases, early clinical trials with novel anticancer agents, as well as large scale registration and translational trials for rare subgroups, including male and inflammatory breast cancer. It has also led to preclinical and clinical molecular imaging studies, with regard to visualization of tumor-specific targets, including cancer drug targets. She received a Clinical Research Award from the Dutch Cancer Society for her grant application: Molecular imaging to guide targeting the breast cancer microenvironment. She is member of several institutional and (inter)national boards including the Dutch Cancer Society Scientific Board and the French Institute National du Cancer Scientific Board. She is involved in national breast cancer guideline development. She is involved in national and international collaboration networks, including Institute Jules Bordet in Brussels, Belgium and the Dana-Farber Cancer Institute in Boston, MA, USA. She is member of international research consortia regarding male breast cancer and inflammatory breast cancer. She is currently supervising 8 PhD students and has published over 90 scientific publications (H-score: 25) including 25 publications as first or senior author. Since 2008, she received a total budget of 5 million euro from different institutions (including Dutch Cancer Society, Dutch Pink Ribbon Foundation) as main applicant and 11,6 million euro as co-applicant. Carolien Schröder is an all-round academic medical oncologist, board certified in Internal Medicine and Medical Oncology. She participates in all aspects of clinical care in the department of Medical Oncology: outpatients, clinic, and consultations. She participates in training of MD students, internal medicine residents and medical oncology fellows. She holds a university teaching qualification from the University of Groningen. As an acknowledged opinion leader in the field of breast cancer, she has a particular interest in reflecting and explaining oncology developments for various audiences including professionals, patients and lay people.

See COI

Anne Simmenroth

Anne Simmenroth

Universitätsklinikum Würzburg, Family Medicine

Würzburg, Germany

Disease area: COVID-19

Biography:
Professor Anne Simmenroth M.D., Ph.D., is a general practitioner specialised in palliative care and since December 2017 both Distinguished Professor and Director of the Institute for General Practice at the University Hospital, Würzburg, Germany. She is the German delegate for EURACT. She got her diploma in Medical Studies in Göttingen, where she also obtained her doctoral degree in 2003 with a thesis on “The prescription of opioids in the general practice – an intervention study”. In Göttingen, she was awarded habilitation and venia legendi in 2015 on the subject “Teaching and examining communicative competence in Medical Studies”. She received awards for distinguished teaching (Rainer-Herken-Award, Medical school Göttingen, 2009) and for teaching (“Interprofessional competencies of medical studies students and students of the nurse’s training school“, Medical school Göttingen, 2014). Her teaching focuses on communicative and social competencies in Medical Studies, on practical skills in the skills lab, on simulated patients as well as courses on prevention of addiction, motivational consulting/behaviour modification. Her research is oriented towards teaching, didactics of examination (Objective Structured Clinical Examination, State examination) and work on simulated patients. She authored several international papers and contributed to national books.

See COI

Christos Sotiriou

Christos Sotiriou

Jules Bordet Institute, Medical Oncology

Brussels, Belgium

Disease area: Breast cancer

Biography:
Professor Christos Sotiriou graduated from the Medical School of the Université Libre de Bruxelles (ULB) in Brussels, Belgium and obtained his Medical Oncology Specialization in 1999. He completed his PhD in genomics in 2004. Currently, he is Professor in the Medical Department of Medical Oncology at the Jules Bordet Institute and Research Director at the National Fund for Scientific Research (FNRS) in Belgium. He is the head of the Breast Cancer Translational Research Laboratory at the Jules Bordet Institute. His main research focus consists of improving the molecular understanding of breast cancer biology, disease dissemination and progression using state-of-the art “omics” technologies, as well as in developing prognostic and predictive biomarkers for breast cancer. The ultimate goal is to accelerate the translation of basic science discoveries dedicated to breast cancer into the clinic. Professor Sotiriou was Member of the TransALTTO committee of the Breast International Group (BIG) and an Executive Chair/Co-organizer/Member of the Executive Committee of the IMPAKT international conference (2009 to 2017). He is currently member of several scientific committees for international meetings, including SABCS, AACR, EBCC, ECCO and ESMO. He served as advisory council member of the Susan G. Komen for the Cure from 2010 to 2016 and an elected member of the scientific council of the International Agency for Research on Cancer (IARC - World Health Organization) from 2012 to 2016. He was elected as Fellow of the European Academy of Cancer Sciences in October 2010 and associated editor of Annals of Oncology since 2014. He is also a core Faculty Member of the European School of Oncology since 2017. Professor Sotiriou’s work has resulted in several patents and in over 250 original research publications, including numerous papers in New England Journal of Medicine, Nature, Nature Medicine, PNAS, JNCI, Journal of Clinical Oncology and Lancet Oncology. He is the recipient of several prestigious national and international awards.

See COI

Martin Spahn

Martin Spahn

University Hospital Bern, Urology

Bern, Switzerland

Disease area: Prostate cancer

Biography:
Dr Martin Spahn is currently Senior Consultant at the Center of Urology at the Hirslanden Klinik Zürich, Prostate Cancer Center Hirslanden Zürich. He is Prof. of Urology at the university of Essen, Germany. His professional career started in Germany where he was born: he graduated in Medicine in 1993 and specialized in Urology and Surgical Urology in 2001 at the University of Mannheim. In 2007 he was appointed Adjunct Clinical Head at the Department of Urology of the Community Hospital Karslruhe, Germany and from 6/2007 on at the Department of Urology and Pediatric Urology at the University Hospital in Würzburg, Germany where he worked until 2012 before moving to the Inselspital Bern, University Hospital, Bern, Switzerland. Dr Spahn is member of several scientific societies, including AUA, EAU. He serves as member of the Steering Committee of the Genito-Urinary Group of the EORTC since 2013. He is PI (Principal Investigator) of a large translational Research project (SPECTApros), an EORTC Reseach platform. He has published over 100 papers in peer-reviewed journals. Dr Spahn is reviewer for several journals including European Urology, British Medical Journal, Journal of Urology and serves as a grant reviewer for several scientific organisations in europe including Cancer Research UK, German Cancer League and Swiss National Fund. He received several awards for his translational resarch in high risk Prostate Cancer including the Prostate Cancer Research Award of the EAU in 2015 and the Urological Oncology Award of the EAU in 2011.

See COI

Cora Sternberg

Cora Sternberg

Weill Cornell Medicine, Medical Oncology

New York, USA

Disease area: Renal Cell Carcinoma

Biography:
Dr. Cora Sternberg is Full Professor of Medicine and the Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, NY, USA. A graduate of the University of Pennsylvania undergraduate and medical schools, she completed her fellowship and was on staff at Memorial Sloan Kettering Cancer in NY. Dr. Sternberg is an internationally respected leader in the fields of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is the principal investigator for numerous studies and an internationally respected researcher who has lectured extensively at universities and cancer symposia worldwide. Dr. Sternberg is particularly known for her influential work in bladder cancer and for her publications on novel therapies for prostate cancer and targeted agents in renal cell carcinoma. Dr. Sternberg has published extensively (more than 406 articles, 6 textbooks) and is an associate editor and editorial board member of several international journals and is a member of the European School of Oncology (ESO) core faculty. Dr. Sternberg has been elected and this year chairs the nominating committee of ASCO’s board of directors.

See COI

Johan Stranne

Johan Stranne

Sahlgrenska University Hospital, Urology

Göteborg, Sweden

Disease area: Prostate cancer

Biography:
Dr. Johan Stranne is an associate professor at the Sahlgrenska Academy, Gothenburg University and a senior consultant at the Department of Urology at the Sahlgrenska University Hospital, Gothenburg, Sweden. He obtained his medical degree from the University of Lund, Sweden in 1997. Following a 2-year internship in Trollhättan, he received his medical licence in 1998. Afterwards, he became a resident at the Department of Urology at the Sahlgrenska University Hospital in Gothenburg. He was accredited as specialist in urology in 2003, and he passed the European Board of Urology specialist exam in Urology (FEBU) in 2004. He has been active as a consultant in urology in the Sahlgrenska University Hospital ever since. Dr. Stranne’s clinical research focuses on treatment of localised prostate cancer with a minimization of side effects. In 2006, he obtained his PhD from the University of Gothenburg with a dissertation about inguinal hernia after urological surgery in males, with specific reference to radical retropubic prostatectomy. He published several peer-reviewed articles on this topic, as well as on robot-assisted radical prostatectomy, PSA-screening, LUTS and ED. Currently, Dr. Stranne is doing research in several clinical studies on prostate cancer and radical prostatectomy, such as the SPCG 15 (RCT of RT + HT vs RP of locally advanced PC), SPCG 17 (active surveillance), the Gothenburg 2 study (PSA-screening) and the LAPPRO-study (prospective comparison RRP vs RALP). Dr. Stranne is member of several national and international urological societies, such as the Scandinavian Prostate Cancer Group (SPCG), European Association of Urology and the Swedish Urological Association.

See COI

Michiel Strijbos

Michiel Strijbos

AZ Klina, Medical Oncology

Antwerp, Belgium

Disease area: Prostate cancer

Biography:
Dr. Michiel Strijbos is a Consultant Medical Oncologist at the AZ Klina hospital in Brasschaat, Antwerp. He was trained at Leuven University in Belgium and the Erasmus University in Rotterdam, The Netherlands, where he graduated in 2004. Between 2004 and 2009, he enrolled in a PhD project focusing on tumor vasculature at the Daniel den Hoed Cancer Center in Rotterdam, for which he was awarded a PhD. Dr. Strijbos received his board certification in Medical Oncology in 2014. In his daily practice, Dr. Strijbos focuses on the research and treatment of genitourinary malignancies, as well as sarcoma. He is currently active in several task forces and committees with regards to GU malignancies and is a principal investigator in several clinical trials in this field. He is also a member of the ESMO GU Faculty, EORTC GU group, and serves as an associate editor for the ESMO Open GU section, and co-authored several book chapters related to GU malignancies.

See COI

Cristina Suárez

Cristina Suárez

Vall d’Hebron University Hospital, Medical Oncology

Barcelona, Spain

Disease area: Renal Cell Carcinoma

Biography:
Dr Suárez received her MD in Medicine and Surgery in 2001 at the Autonomous University of Barcelona, Spain. She obtained a Specialist Training in Medical Oncology at the Faculty of Medicine, Autonomous University of Barcelona—Hospital del Mar. In 2008, she joined the Oncology Department of Vall d’Hebron University Hospital as physician (attending staff) of the Genitourinary, Central Nervous System, Sarcoma and Tumors of Unknown Origin Program. In 2018, she completed her doctoral studies cum laude with her doctoral thesis entitled “Prognostic value of genetic alterations in the mTOR pathway of patients with metastatic renal cell carcinoma treated with mTOR inhibitors”. Since 2008, Dr Cristina Suárez has been the Co-investigator and Principal Investigator in several clinical trials related to genitourinary malignancies. She is also the (co-)author of more than 80 national and international scientific papers, posters and book chapters, especially focused in the area of genitourinary tumors.

See COI

Rana Tahbaz

Rana Tahbaz

Elbe Kliniken, Urology

Hamburg, Germany

Disease area: Renal Cell Carcinoma

Biography:
Dr Rana Tahbaz is a senior consultant in Urology at the Elbe Kliniken, academic teaching Hospital of the University Hospital Hamburg-Eppendorf in Germany She specialises in uro-oncology with focus on kidney cancer. Dr Tahbaz completed her urology residency training at the University Hospital Hamburg-Eppendorf in Germany. She subsequently completed a clinical fellowship in Urologic Oncology at the University Cancer Center Hamburg, Germany. After completion of her training she joined the Elbe Kliniken.

See COI

Arnoud Templeton

Arnoud Templeton

St. Claraspital, Medical Oncology

Basel, Switzerland

Disease area: Prostate cancer,Renal Cell Carcinoma

Biography:
PD Dr. Arnoud J. Templeton is a staff medical oncologist at the Department of Medical Oncology St. Claraspital Basel, Switzerland, and group leader oncological and general research. Dr. Templeton graduated in medicine at the university of Basel and gained his MD in 2003. He completed his medical training in St. Gallen with the Swiss board certification in Internal Medicine and Medical Oncology. He attended the Flims Workshop Methods in Clinical Cancer Research in 2008 and did a clinical research fellowship at the Princess Margaret Cancer Centre in Toronto 2012-2014 under the supervision of Professor Ian Tannock. He was a staff medical oncologist at the Department of Medical Oncology Kantonsspital St. Gallen and worked for the Swiss Group for Clinical Cancer Research (SAKK) as Medical Advisor before accepting his current position. › His major clinical and research interest is urogenital malignancies and markers of host inflammation. Dr. Templeton has published more than 100 peer reviewed articles and is a regular reviewer for several journals. Dr. Templeton is a member of a number of societies, including the European Society of Medical Oncology (ESMO), and the Swiss Medical Association (FMH). His major clinical and research interest is prostate cancer and markers of inflammation. He has been co-investigator in several phase I – III trials and is co-principle investigator of a large multicentre trial conducted in Switzerland and has published more than 90 peer-reviewed articles as author or co-author. Dr. Templeton is a regular reviewer for various oncologic and urologic journals and is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the Swiss Group for Clinical Cancer Research (SAKK), and the Swiss Medical Association (FMH).

See COI

Camilla Thellenberg Karlsson

Camilla Thellenberg Karlsson

Umeå University, Clinical Oncology

Umeå, Sweden

Disease area: Prostate cancer,Renal Cell Carcinoma

Biography:
Dr. Camilla Thellenberg Karlsson is a senior consultant at the Department of Oncology, Cancercentrum at Umeå University Hospital and a PhD researcher at the Department of Radiation Sciences, Oncology at Umeå University. She obtained her medical degree from the University of Umeå in 1997 followed by an 2-year internship in Sundsvall to provide for the medical licence in 1998. After that she returned to Umeå and became resident at the Department of Oncology, Cancercentrum at Umeå University Hospital. Following this path she became accredited as a specialist in Oncology 2006 and has ever since worked as a consultant and focused her clinical work on Uro-oncology, mainly Prostate Cancer. The research questions were first focused on genetic epidemiology and her thesis was defended in 2008. After that focus has mainly been on clinical studies trying to improve treatment for both localised and disseminated prostate cancer. She is at present Process leader of Prostate Cancer in the Northern region of Sweden and Head of the Swedish Uro-Oncology Society as well as a board member of the international urological society, Scandinavian Prostate Cancer Group SPCG.

See COI

Derya Tilki

Derya Tilki

University Hospital Hamburg-Eppendorf, Urology

Hamburg, Germany

Disease area: Prostate cancer

Biography:
Dr. Derya Tilki is an Associate Professor of Urology at the Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf in Germany specializing in prostate cancer. Dr. Tilki completed her urology residency training at the Ludwig-Maximilans-University in Munich. She subsequently completed a clinical fellowship in Urologic Oncology at UC Davis in Sacramento. After completion of her training she joined the Faculty at the Martini-Klinik Prostate Cancer Center. Dr. Tilki is on the Editorial Board for European Urology and the British Journal of Urology International. She has published over 200 peer-reviewed articles and 4 book chapters. Dr. Tilki is an Associate Editor of European Urology Focus.

See COI

Bertrand Tombal

Bertrand Tombal

University Hospital Saint-Luc, Urology

Brussels, Belgium

Disease area: Prostate cancer

Biography:
Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine. He is the Member of the Board of European Organization for Research and Treatment in Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003. Professor Tombal is also member of Belgium College of Oncology, the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology.

See COI

Levent Türkeri

Levent Türkeri

Academic Hospital, Urology

Istanbul, Turkey

Disease area: Prostate cancer

Biography:
Levent Türkeri MD, PhD is a Professor of Urology at Acıbadem University School of Medicine in İstanbul, Turkey. He is a Uro-oncologist with expertise in robotic, laparoscopic and open surgery. His research interest involves molecular aspects of diagnosis and prognostic factors of urological malignancies along with clinical trials. Currently, he is serving as the Board member of Urooncology Association of Turkey, Director of School of Urology and Coordinator of Board of Urology at Society of Urological Surgeons (Turkey) and also actively involved in a number of national and international urological societies such as AUA, EAU, URS, AAEU, ESOU, ESUR, EORTC. Area of Expertise: Urooncology (Prostate Cancer, Bladder Cancer, Kidney Cancer, Testis Cancer), Urologic Surgery (open, laparoscopic, robotic surgery), Molecular Urology

See COI

User avatar

Péter Vajer

Semmelweis University, Family Medicine

Budapest, Hungary

Disease area: COVID-19

Biography:
To be added

Jean-Paul Van Basten

Jean-Paul Van Basten

Canisius-Wilhelmina Hospital, Urology

Nijmegen, Netherlands

Disease area: Renal Cell Carcinoma

Biography:
Jean-Paul Arnoldus van Basten is urologist, with special interest in minimal invasive and robotic surgery, at the Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. He received his MD in 1996 at the University of Maastricht. During his study he resided at the University hospital in Medan, Sumatra and did research on typhoid perforation in Kumasi, Ghana. He wrote his thesis entitled ‘Sexual sequelae of testicular cancer’ at the departments of Urology and Surgical Oncology at the University of Groningen. He received his PhD degree in 1999. Dr van Basten has received awards from the Dutch Urological Society as recognitions for his publications and presentations. In 1998 he started his residency in general surgery at the University Hospital in Maastricht and was recruited for Urology in 2001. His residency in urology was continued at the Isala Clinics in Zwolle and University of Groningen. In 2003 Dr van Basten started a fellowship in laparoscopy at the Radboud University and Jeroen Bosch Hospital in the Netherlands. Moreover, he stayed two weeks in New York visiting the Memorial Sloan Kettering Cancer Center. He did a mini-fellowship in robotic surgery at the University of Los Angeles. Dr van Basten is a member of several scientific societies including the European Association of Urology and is a board member of the Dutch Society of Endo-Urology. He is the editor-in-chief of the book ‘Dutch recommendations in laparoscopic and robotic surgery in urology’, which forms the theoretical basis of the exam in laparoscopic skills for Dutch residents. Dr van Basten is actively involved in teaching residents and fellows in laparoscopic and surgery and is official proctor in robotic surgery. He supervises several PhD students and is value-based healthcare lead in prostate cancer of the Santeon hospital alliance. He is proud to be involved in the Mirrors of Medicine programme.

See COI

Frank Van der Aa

Frank Van der Aa

University Hospitals Leuven, Urology

Leuven, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Frank Van der Aa is adjunct head of clinic in the Department of Urology in the University Hospitals Leuven and staff member of the National MS Center in Melsbroek, both in Belgium. In addition, he is lecturer of the Faculty of Medicine at the Catholic University of Leuven. His special clinical interests are in neuro-urology, male and female incontinence and reconstructive urology. His major research interest include animal models of stress urinary incontinence, interstitial cells, nerve regeneration and stem cell applications. He received his MD in 2001 from the Catholic University of Leuven and obtained his PhD in Medical Sciences in 2007 from the same university. He completed his residency in Urology in 2008 at UZ Gasthuisberg in Leuven. He became Fellow of the European Board of Urology (FEBU) in 2010 and Fellow of the European Board of Sexual Medicine (FECSM) in 2012. He is faculty member of the European School of Urology (ESU) since 2009, Editorial Board member of Neurourology and Neurodynamics since 2011, and member of the Video Congress Committee of the European Association of Urology (EAU) Scientific Congress Office since 2012. He is board member of the EAU section of Female and Functional Urology since 2012 and president of the working group functional urology of the Belgian Association of Urology (BAU).

See COI

Philip Van Kerrebroeck

Philip Van Kerrebroeck

Maastricht University Medical Center, Urology

Maastricht, Netherlands

Disease area: Lower Urinary Tract Dysfunction

Biography:
Philip E.V. Van Kerrebroeck, MD, PhD, MMSc, was born in Leuven, Belgium, where he also obtained his medical degree with distinction from the University of Leuven in 1978. He trained in General Surgery and Urology in Belgium and the Netherlands and was registered as urologist in 1984. He received a master’s degree in medicine from the University of Antwerp, Belgium in 1992 and a PhD degree in Medical Sciences from the University of Nijmegen, the Netherlands in 1993. Since 1993, he is a fellow of the European Board of Urology. Philip Van Kerrebroeck has experience as a urologist at the Department of Urology of the Radboud University Hospital in Nijmegen and was consultant at the Spinal Cord Unit of the St Maartens Hospital from 1988 till 1996. In 1996 he followed additional training in Neuro-Urology with Professor Tanagho at the University of California, San Francisco, CA, USA, and was appointed as professor of Neuro-Urology at the University of Maastricht in August 1996. From September 1997 till August 2012, Philip Van Kerrebroeck was chairman of the Department of Urology in the Maastricht University Hospital Maastricht (MUMC+). From November 1998 till November 2019 he was professor of Urology at the University of Maastricht and worked as urologist in the Department of Urology of the MUMC+. Since November 2019 he is professor emeritus. Professor Van Kerrebroeck is board member of the European Association of Urology (EAU) and of the International Continence Society (ICS). He was chairman of the ICS Standardisation Committee between 2000 and 2007. He is currently chairman of the History Office of the EAU. Professor Van Kerrebroeck has a broad clinical experience in different forms of lower urinary tract dysfunction in men and women. His research interests are focused on new therapies in Functional Urology such as pharmacotherapy and neuromodulation for voiding dysfunction. Recently he became also involved in the history of Urology with a specific interest in Urological Surgery and Urology in France in the 19th century. Professor Van Kerrebroeck is member of 25 scientific societies and sits on the Editorial Board of 6 scientific journals. In addition, he is reviewer for 7 urological journals. He authored 14 books, 32 book chapters and 312 scientific articles in peer-reviewed journals. Philip Van Kerrebroeck has working as an urologist at the Department of Urology of the Radboud University Hospital in Nijmegen and was consultant at the Spinal Cord Unit of the St Maartens Hospital from 1988 till 1996. In 1996 he followed additional training in Neuro-Urology with Professor Tanagho at the USCF in San Francisco, and was appointed as Professor of Neuro-Urology at the University of Maastricht in August 1996. From September 1997 till August 2012, Philip Van Kerrebroeck was Chairman of the Department of Urology in the Maastricht University Hospital Maastricht (MUMC+). Since November 1998 he is Professor of Urology at the University of Maastricht and works as urologist in the Department of Urology and the Pelvic Care Centre of the MUMC+. Professor Van Kerrebroeck is past Board member of the International Continence Society (ICS) and past-chairman of the ICS Standardisation Committee. He is currently member of the History Office of the EAU. Professor Van Kerrebroeck has a broad clinical experience in different forms of lower urinary tract dysfunction in men and women. His research interests are focused on new therapies in Functional Urology such as pharmacotherapy and neuromodulation for voiding dysfunction. Recently he got also involved in the history of Urology with a specific interest in Urological Surgery and Urology in France in the 19th century. Professor Van Kerrebroeck is member of 25 scientific societies and sits on the Editorial Board of 6 scientific journals. In addition, he is reviewer for 7 urological journals. He authored 14 books, 32 book chapters and 312 scientific articles in peer-reviewed journals.

See COI

Jeroen van Moorselaar

Jeroen van Moorselaar

VUmc Cancer Centre Amsterdam, Urology

Amsterdam, Netherlands

Disease area: Prostate cancer,Renal Cell Carcinoma

Biography:
Jeroen van Moorselaar studied Medicine at the University of Nijmegen in the Netherlands and obtained his medical degree in June 1987. He continued his career as research fellow in the urological research laboratory of the Urology Department at the University Hospital in Nijmegen where he did his PhD entitled ‘Cytokine Therapy in Experimental Urological Cancer’ in 1991. He was certified as urologist in June 1997. From that time he has worked in the University Hospital in Nijmegen in the Urological Department and in April 1998 he moved to the University Hospital in Utrecht where he worked until August 2005. In September 2005 he became the head of the Urological Outpatient Department at the VU University Medical Centre in Amsterdam where he still works, but since August 2008 in the position of Chairman. In March 2011 he was appointed as Professor of Urology. He is member of various national and international organizations. He is member of the Dutch working party on urological oncological guidelines and is founding member of the Dutch UroOncology Studygroup. Since May 2007 he is board member of the European School of Urology. Furthermore he is Incoming President of the European Board of Urology. He is an active researcher in the field of Urological Oncology. He has published over 180 peer reviewed papers and book chapters.

See COI

Inge van Oort

Inge van Oort

University Medical Centre Radboud, Urology

Nijmegen, Netherlands

Disease area: Prostate cancer

Biography:
Dr. Inge van Oort completed her urological training at het Radboud University Nijmegen Medical Centre, the Netherlands, in 2006. In that same year she started her fellowship in oncological urology and she also became part of the faculty at the Radboud University Nijmegen Medical Centre (chairman: Peter Mulders). In 2008 she was appointed as an oncological urologist and senior staff member. In 2009, she obtained her PhD on the clinical relevance of pathological findings after radical prostatectomy at the department of Urology at the Radboud University Nijmegen Medical Centre. Her main interest in oncological urology is the (surgical) treatment of prostate and bladder cancer. In research she has interests in finding new molecular markers in prostate cancer and in the treatment of castration resistant prostate cancer. She also has been part of several large trials in CRPC (i.e Cougar 301 and 302 (abiraterone), Proselica and compassionate use program (cabazitaxel), Affirm and Previal (enzalutamide), provenge (sipuleucel-T), orteronel. On national level she has been part of several activities at the Dutch Urological Society(DUA). She was the chair of the working group on Oncological Urology (WOU) for 7 years, member of the board of education for residents (CCO), and member of the “Quality of care” group. She is member of the multidisciplinary Dutch guideline group on prostate cancer. At the EAU she’s a member of the EAU Guideline Office- new media group and was part of the Young academic Urologists (prostate cancer group) from 2011-2014. In 2013 she received a grant from the Dutch cancer foundation for a study on Quality of care in prostate cancer treatment and in 2015 a grant from the ZonMW for a study on tumor response markers in combination with drug exposure measurement. Inge M. van Oort is member of national and international urological and oncological associations. She is also reviewer for national and international journals and member of the editorial board of the world journal of Urology.

See COI

Charles Van Praet

Charles Van Praet

Ghent University Hospital, Urology

Ghent, Belgium

Disease area: Renal Cell Carcinoma

Biography:
Charles Van Praet is a urologist at Ghent University Hospital in Belgium. He received his medical degree in 2012. He completed his PhD in 2017 with a thesis on “Novel treatments in prostate cancer”. After finishing his residency in urology in 2019, he became a fellow of the European Board of Urology. He is a member of national and international associations. His main focus is treatment of prostate and kidney cancer and minimal-invasive surgery. Currently, he is an investigator in multiple clinical and academic trials.

See COI

Josep M. Vilaseca

Josep M. Vilaseca

WONCA Europe, Family Medicine

Barcelona, Spain

Disease area: COVID-19

Biography:
Josep Vilaseca graduated in medicine in 1995 in the University of Barcelona. He completed the Specialist in Family and Community Medicine Training in 2001. He obtained his PhD in Medicine and Surgery in 2005. Later on, he completed an MBA (2008) and a MSc in Public Health (2012). Dr. Vilaseca has been working as a practitioner since 1996 in several hospital and primary health care units. Since March 2002 he is working as a Family Doctor in Barcelona city at Consorci d'Atenció Primària de Salut Barcelona Esquerra (former Consorci d’Atenció Primària de Salut de l’Eixample). Since 2017 he is Associate Professor at the University of Barcelona and Associated Professor at the University of Vic – Central Catalonia University. His academic career includes collaborations as a professor in the OBS Business School and as a tutor in the UPF – Barcelona School of Management. Dr. Vilaseca has been a medical advisor in Altermutua dels advocats de Catalunya between 2009 and 2019. He took the role of public health officer (2008 - 2010) and of Project General Manager in the Innovation Plan for Primary Health Care in the Department of Health of Catalonia (2010 – 2012). He held the post of treasurer of the Spanish Society of Family doctors between 2003 and 2007. In 2010 he became a member of the Statutory Committee of Finance at WONCA Europe. In 2016 he was elected as the honorary treasurer of WONCA Europe. He was elected Delegate in the Executive Board at the Medical College of Barcelona in 2014 and in 2019. His areas of interest concern Family Medicine (previously digestive disorders, now diabetes mellitus) and Health Care Services Management and Organization (Primary Care and Integrated Care). He is also a researcher in the history of medicine.

See COI

Ursula Vogl

Ursula Vogl

Ospedale San Giovanni - IOSI, Medical Oncology

Bellinzona, Switzerland

Disease area: Bladder cancer

Biography:
To be added

See COI

Jochen Walz

Jochen Walz

Paoli-Calmettes Institute Cancer Centre, Urology

Marseille, France

Disease area: Prostate cancer

Biography:
Jochen Christoph Walz, MD is the head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France. He was chairman of the EAU Section of Urological Imaging from 2009 to 2017. Dr. Walz attended the Medical School of the University of Mainz, Germany. He completed his dissertation at the University of Mainz about “Mechanisms of mutagenesis of ultimate geno-toxique substances influenced by homogenate of human erythrocytes”. Afterward, he completed his residency in Urology at the University of Marseille, France and Hamburg, Germany. He is board certified urologist since 2005. He became a research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montreal, Canada in 2006-2007 and received his “Habilitation” in 2008 in Urology at the University of Hamburg, Germany. He is specialized in urooncology and urological imaging.

See COI

Maria Wendler

Maria Wendler

EURACT, ÖGAM & Karl Landsteiner Private University, Family Medicine

Krems, Austria

Disease area: COVID-19

Biography:
Doctor Maria Wendler studied at Medical University of Graz, was awarded Doctor of Medicine (Dr. med. univ.) in February 2011 and received the ius practicandi in 2015. In 2019 she joined EURACT as Europe Council member representing Austria. Since March 2020 she is a Member of the Scientific Staff, Department of General Health Studies, Division General an Family Medicine, Karl Landsteinter Private University Krems – where her main area of responsibility is the Point-of-Care-Tool: “Covid-19: Prevention and Management in the Primary care setting (of GP/FM)” with focus on time - knowledge transfer to Family physicians about COVID-19 and all its implications for daily routine in GP/FM (Diagnosing and Testing, Vaccinations, office-management, PPE, patient care etc.). Over the years she has taken part to different projects. Since October 2020, Maria takes part to the External Teaching Staff, Medical University of Graz, Institute of General Practice and Evidence based Health Services Research. She is an active member of the ÖGAM (Austrian Society of General Practice and Family Medicine) and JAMÖ (Young GPs in Austria) since 2010, and she acted president of JAMÖ between 2012 and 2016. Between 2013 and 2017 Maria was a member of VdGM (Vasco da Gama Movement of WONCA Europe - Europe Council Member), and since 2016 she assumed the role of honorary Secretary (rep.) of ÖGAM since 2016.

See COI

Thomas Wiegel

Thomas Wiegel

University Hospital Ulm, Radiation Oncology

Ulm, Germany

Disease area: Prostate cancer

Biography:
To be added

See COI

Hans Wildiers

Hans Wildiers

University Hospitals Leuven, Medical Oncology

Leuven, Belgium

Disease area: Breast cancer

Biography:
Hans Wildiers is a medical oncologist dedicated to breast cancer research and geriatric oncology. He is staff member at the Department of Medical Oncology in the University Hospital Leuven, Belgium since 2004. He coordinates the Leuven Multidisciplinary Breast Centre since 2015. He has been coordinator of several academic studies in the field of breast cancer and geriatric oncology, and author of more than 250 peer-reviewed papers. He has been active within the board of SIOG, the international society of geriatric oncology, for many years, and serves this organisation as president from November 2018 until October 2020. From 2009 until 2015, he has chaired the elderly task force ‘Cancer in Elderly’ of the European Organisation of Research and Treatment of Cancer (EORTC).

See COI

Adam Windak

Adam Windak

Jagiellonian University Medical College, Family medicine

Krakow, Poland

Disease area: COVID-19

Biography:
Professor Adam Windak M.D, Ph.D. is a Full Professor and Head of the Department of Family Medicine at Jagiellonian University Medical College, Kraków, Poland. He also works as a family physician in a group practice in Kraków. He is a Funder, Past President and current Vice-President of the College of Family Physicians in Poland. He coordinated several international educational projects (Tempus, Leonardo da Vinci) financed by the European Union. Prof. Windak was a leader of several research projects and is author of over three hundreds national and international publications. Cumulated Impact Factor of all his publications is 132 with a total number of citations 835 (h-index 13). He is an Associated Editor of the European Journal of General Practice. His research interest includes health service sciences, medical education and quality of primary health care with special focus on cardiovascular diseases.

See COI

Youssef Zeidan

Youssef Zeidan

American University of Beirut, Radiation Oncology

Beirut, Lebanon

Disease area: Breast cancer

Biography:
Dr. Zeidan is Associate Professor of Radiation Oncology and residency program director at the American University of Beirut. He received his dual MD/PhD degree from the Medical University of South Carolina in 2009. This was followed by four years of residency training in Radiation Oncology at Stanford University (2010-2014) where he served as Chief Resident (2013-2014). He was appointed as Assistant Professor of Radiation Oncology at the University of Miami (2014-2016) where he directed the radiobiology program. Along with several other co-investigators, he authored more than 30 peer-reviewed publications in the field. This work was recognized by several grants and awards from the radiological society of North America (RSNA) and the American Society for Radiation Oncology (ASTRO).

See COI

Thomas Zilli

Thomas Zilli

University of Geneva, Radiation Oncology

Geneva, Switzerland

Disease area: Prostate cancer

Biography:
Dr Zilli is a faculty at Geneva University Hospital, Switzerland, where is working as a senior clinician and vice-chief in the Division of Radiation Oncology. He graduated in Medicine and Surgery in 2004 at University of Udine (Italy) and specialized in Radiation Oncology at the Geneva University Hospital, Switzerland. He completed a 1-year fellowship in prostate brachytherapy at the Centre Hospitalier de l'Université de Montréal (CHUM), Canada. He obtained the Privat-Docent at the Faculty of Medicine of Geneva in 2015 and the Chargé de Cours title in March 2017. He is responsible for the treatment of prostate and genitourinary tumors at Geneva University Hospitals and actively involved since its creation in 2014 in the organization of the Geneva Prostate Cancer center. Main research includes mainly the treatment of prostate cancer patients using modern high-precision radiotherapy techniques including IMRT, VMAT and SBRT as well as the use of molecular imaging in the radiotherapy planning and the treatment of gastrointestinal tumors. He already published 70+ original peer-reviewed articles and he serves as reviewer for different peer-review journals including IJROBP, Radiotherapy and Oncology, Radiation Oncology, Acta Oncologica. He is actively involved in the GFRU (Groupe Francophone de Radiothérapie Urologique) association and active member of the European Organisation for Research and Treatment of Cancer (EORTC) and Swiss Group for Clinical Cancer Research (SAKK).

See COI